5-and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinase

By developing 5- and 6-azaindole compounds that selectively inhibit Bcr-Abl tyrosine kinase, the drug resistance and side effects caused by T315I mutation in the prior art were solved, and the therapeutic effect on CML was improved.

CN119019388AActive Publication Date: 2024-11-26ENLIVEN THERAPEUTICS INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411122661.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-07-21
Filing Date
2021-10-04
Publication Date
2024-11-26
Estimated Expiration
2041-10-04

AI Technical Summary

Technical Problem

The existing Bcr-Abl tyrosine kinase inhibitors have reduced effects in the face of T315I mutations, resulting in tolerability and selectivity problems in treating CML patients, and side effects lead to dose adjustment and discontinuation, affecting the treatment effect.

Method used

Provided a 5- and 6-azaindole compound that selectively inhibits Bcr-Abl tyrosine kinase for the treatment of disorders mediated by Bcr-Abl tyrosine kinase through specific compound structures with Bcr-Abl The high affinity binding of tyrosine kinase inhibits its activity.

Benefits of technology

It improves drug resistance and selectivity to T315I mutations, reduces side effects, extends the treatment cycle, and improves the effect of treating CML.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004995524830000031
    Figure BDA0004995524830000031
  • Figure BDA0004995524830000081
    Figure BDA0004995524830000081
  • Figure BDA0004995524830000082
    Figure BDA0004995524830000082
Patent Text Reader

Abstract

The present disclosure relates to compounds and compositions for inhibiting Bcr-Abl tyrosine kinase, methods of making the compounds and compositions, and uses of the compounds and compositions in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application filed on October 4, 2021, with application number 202180080488.1 and entitled "5- and 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase".

[0002] Cross-references to related applications

[0003] This application claims priority and interest in U.S. Provisional Application No. 63 / 087,763, filed October 5, 2020, and U.S. Provisional Application No. 63 / 224,236, filed July 21, 2021, the disclosure of each of which is incorporated herein by reference in its entirety. Technical Field

[0004] This article provides compounds and compositions for inhibiting Bcr-Abl tyrosine kinase, methods for preparing said compounds and compositions, and the use of said compounds and compositions in the treatment of various cancers such as chronic myeloid leukemia (CML). Background Technology

[0005] The Philadelphia chromosome, a cytogenetic abnormality, is highly associated with the development of many hematologic malignancies, including most chronic myeloid leukemias (CML) and a subset of acute lymphoblastic leukemias (Ph+ALL). The Philadelphia chromosome is the product of a translocation between a breakpoint cluster region (BCR) gene on chromosome 22 and an Abelson (ABL) tyrosine kinase gene on chromosome 9, resulting in an oncogenetic fusion gene product, Bcr-Abl. This fusion protein is overexpressed and possesses constitutive kinase-promoting activity, which then drives the activation of numerous intracellular signaling cascades to induce uncontrolled cell growth, division, and survival associated with oncogenic transformation. Therefore, therapeutic interventions using Bcr-Abl tyrosine kinase inhibitors represent the cornerstone of current treatment modalities for patients with Philadelphia-positive tumors.

[0006] Imatinib (STI-571), a small-molecule Bcr-Abl tyrosine kinase inhibitor (Bcr-AblTKI), was developed in the early 1990s as a potent treatment for CML and remains a first-line therapy for the disease. However, in more aggressive cases of CML, patients often relapse due to the development of resistance. The main mechanism of this resistance stems from a variety of intermediate-target genetic alterations that drive aberrant overexpression of the Bcr-Abl fusion compound, or more commonly, the introduction of amino acid mutations within the Abl kinase domain that reduce the binding affinity of imatinib to its active site, thereby significantly reducing its inhibitory activity. These alterations can occur randomly and represent subsets of the initial tumor cell population, or they can emerge under selective pressure from inhibitor therapy. One major intermediate-target Bcr-Abl resistance mutation originates from a point mutation that introduces an isoleucine residue at position 315 (also known as the “gatekeeper” position) within the Abl kinase domain, replacing a threonine residue (T315I). Besides imatinib, this mutated form of BCR-Abl exhibits significant resistance to all second-generation Bcr-Abl TKIs (nilotinib, dasatinib, bosutinib, and radotinib). Currently, for patients with the T315I mutation, only one treatment option exists—the third-line Bcr-Abl TKI ponatinib. While effective in treating T315I CML patients, ponatinib exhibits poor selectivity for Bcr-Abl compared to many other protein kinases. Consequently, significant dose-limiting toxicities have been reported with ponatinib, which then restrict its ability to effectively bind to its target and achieve clinical efficacy.

[0007] Besides on-target or off-target resistance, intolerance to Bcr-Abl TKIs also represents a major clinical challenge. More than 50% of Ph+ leukemia patients require dose modifications due to adverse events. In fact, approximately 30% of patients are forced to reduce their dose within the first 6 months of treatment. These drug-related side effects occur early in the treatment process and, while manageable in most cases, toxicity persists, significantly impacting patients' quality of life and leading to decreased adherence. Consequently, around 40% of patients discontinue first- and second-generation Bcr-Abl TKIs within the first 5 years of treatment. All currently approved Bcr-Abl targeted therapies inhibit other tyrosine kinases, which can lead to potentially debilitating side effects. Specifically, potent inhibition of VEGFR, PDGFR, c-Kit, and / or the c-Src family can cause dose-limiting side effects in patients. To address these side effects, dose reduction, dose interruption, and even dose discontinuation are often required during treatment; however, such treatment regimens ultimately result in suboptimal treatment outcomes.

[0008] Therefore, there remains a significant unmet medical need for Bcr-Abl TKIs that offer improved selectivity in Philadelphia positive cases to enhance tolerability and have enhanced potency against broad resistance mechanisms. Summary of the Invention

[0009] This article provides compounds and compositions that selectively inhibit Bcr-Abl tyrosine kinase and can be used to treat conditions mediated by Bcr-Abl tyrosine kinase.

[0010] On the one hand, this paper provides a compound of formula (I),

[0011]

[0012] Or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein:

[0013] X is NR 3’ or CR 3 ,

[0014] Y is NR 2 or CR 4 ,

[0015] Where X is NR 3’ When, then Y is CR 4 Y has up to CR 5 The double bond, and X has up to CR 5 A single bond; or when X is CR 3 When Y is NR 2 Y has up to CR 5 The single bond, and X has up to CR5 Double bonds;

[0016] R 0 as a group

[0017] m is an integer from 0 to 3;

[0018] Each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0019] R 2 It is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0020] R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN;

[0021] R 3’ It can be -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN;

[0022] R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0023] R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0024] R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4 to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0025] Each R 7 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0026] Each R 8 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0027] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein the heterocycles optionally contain 1 to 2 additional heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0028] Each R 9 Independent of halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl,

[0029] Where n is an integer from 0 to 2; and

[0030] Each R 10 Independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group and / or 1-6 deuterium atoms.

[0031] On the other hand, this paper provides a compound of formula (I),

[0032]

[0034] Or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein:

[0035] X is NR 3’ or CR 3 ,

[0036] Y is NR 2 or CR 4 ,

[0037] Where X is NR 3’ When, then Y is CR 4 Y has up to CR 5 The double bond, and X has up to CR 5 A single bond; or when X is CR 3 When Y is NR 2 Y has up to CR 5 The single bond, and X has up to CR 5 Double bonds;

[0038] R 0 as a group

[0039] m is an integer from 0 to 3;

[0040] Each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0041] R 2 It is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0042] R 3It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN;

[0043] R 3’ It can be -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN;

[0044] R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0045] R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0046] R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0047] Each R 7 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0048] Each R 8 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0049] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0050] Each R 9 Independent of halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl,

[0051] Where n is an integer from 0 to 2; and

[0052] Each R 10 Independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group and / or 1-6 deuterium atoms.

[0053] In some embodiments, the compound of formula (I) is the same as the compound of formula (IA):

[0054]

[0055] In some embodiments, the compound of formula (I) is a compound of formula (IAi) or formula (IA-ii):

[0056]

[0057] in

[0058] m is an integer, either 0 or 2;

[0059] Each R 1 Independently -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene groups are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0060] R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3;

[0061] R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN;

[0062] R 3’ It can be -H, C1-C3 alkyl, C3-cycloalkyl or -CN;

[0063] R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen;

[0064] R 5 For C6-C 14 Aryl or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is selected from the group consisting of:

[0065]

[0066]

[0067] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups.9 Group substitution;

[0068] Each R 7 Independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0069] Each R 8 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0070] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0071] Each R 9 Independent of halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and

[0072] Each R 10 Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy and / or 1-6 deuterium atoms.

[0073] In some implementation schemes that can be combined with any of the foregoing implementation schemes, each R 1 Independently -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH; and wherein R 1 Each pair of R 7’ and R 8’ They independently form 4- to 6-membered heterocycles together with the nitrogen atoms to which they are attached, wherein the heterocycles optionally contain an additional 1-2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atom of any primary or secondary amine present in the heterocycle is optionally substituted with H or a C1-C3 alkyl group. In other embodiments that can be combined with any of the foregoing embodiments, R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0074]

[0075] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution. In other embodiments that can be combined with any of the foregoing embodiments, R... 2 For -CH3, CD3, or CH2CH3; R 3 -H, -F, -CH3, or -CN; R 3 'is -H or -CH3; and R 4 It is -H, -F, or -CH3. In further embodiments that can be combined with any of the foregoing embodiments, each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN, and each R 10 Independently -H, -CH3, -CD3 or -CH2CH3, wherein the -CH3 or the -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3.

[0076] In other embodiments that can be combined with any of the foregoing embodiments, the compound of formula (I) is a compound of formula (IAi) or formula (IA-ii):

[0077]

[0078]

[0079] in

[0080] m is an integer, either 0 or 1;

[0081] R 1 -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH;

[0082] R 2 It can be -CH3, CD3, or -CH2CH3;

[0083] R 3 -H, -F, -CH3, or -CN;

[0084] R 3’ -H or -CH3;

[0085] R 4 It can be -H, -F, or -CH3;

[0086] R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0087]

[0088] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution;

[0089] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms in the group consisting of N and O, and wherein the nitrogen atoms of any primary or secondary amines present in the heterocycles are optionally substituted with H or C1-C3 alkyl groups.

[0090] Each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN, and

[0091] Each R 10 Independently -H, -CH3, -CD3, or -CH2CH3, wherein the -CH3 or -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3. In other embodiments that can be combined with any of the foregoing embodiments, the compound of formula (I) is a compound of formula (IAi) or (IA-ii):

[0092]

[0093] in

[0094] m is an integer, either 0 or 1;

[0095] R 1 -F;

[0096] R 2 -CH3;

[0097] R 3 -H or -CH3;

[0098] R 3’ -H or -CH3;

[0099] R 4 -CH3;

[0100] R 5 It is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0101]

[0102] The 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution;

[0103] Each R 9 Independent of -F or -OR 10 ,and

[0104] Each R 10 It can be -H or -CH3 independently.

[0105] In other embodiments of this aspect, the compound of formula (I) is the compound of formula (IB):

[0106]

[0107] In some embodiments of the foregoing implementation schemes, the compound of formula (I) is a compound of formula (IBi) or formula (IB-ii):

[0108]

[0109] in

[0110] R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3;

[0111] R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN;

[0112] R 3’ It can be -H, C1-C3 alkyl, C3-cycloalkyl or -CN;

[0113] R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen;

[0114] R 5 For C6-C 14 Aryl or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is selected from the group consisting of:

[0115]

[0116] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0117] R 6 It is a C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 alkylene-NR 7 R8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0118] Each R 7 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0119] Each R 8 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0120] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0121] Each R 9 Independent of halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and

[0122] Each R 10 Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy.

[0123] In some implementation schemes that can be combined with any of the foregoing implementation schemes, R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ ; and R 6 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In other embodiments that can be combined with any of the foregoing embodiments, R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0124] The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution. In other embodiments that can be combined with any of the foregoing embodiments, each R... 9 Independently -F, -OR 10 -CH3, and each R 10 Independently, it is -H, -CH3, -CD3, -CF2H, or -CF3. In other embodiments that can be combined with any of the foregoing embodiments, R 2 -H or -CH3; R 3 -H;R 3 'is -H; and R 4 It can be H or -CH3.

[0125] In some embodiments that can be combined with any of the foregoing embodiments, the compound of formula (I) is a compound of formula (IBi) or formula (IB-ii):

[0126]

[0127] in

[0128] R 2 -H or -CH3;

[0129] R3 -H;

[0130] R 3 'is -H;

[0131] R 4 -H or -CH3;

[0132] R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0133]

[0134] The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution;

[0135] R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ ;

[0136] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0137] Each R 9 Independently -F, -OR 10 -CH3, and

[0138] Each R 10 It can be -H, -CH3, -CD3, -CF2H or -CF3 independently.

[0139] This article also provides a compound selected from the group consisting of:

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153] Or a pharmaceutically acceptable salt, solvate, hydrate or eutectic, or a mixture of any of the foregoing substances.

[0154] On the other hand, this article provides a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt, solvate, hydrate or cocrystal thereof, or a mixture of any of the foregoing substances, and one or more pharmaceutically acceptable excipients.

[0155] In another aspect, this disclosure provides a method for inhibiting the enzymatic activity of Bcr-Abl in cells, comprising exposing the cells to an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances.

[0156] On another front, this document provides a method for treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia in a person in need, comprising administering to said person a compound of formula (I) as described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances.

[0157] In some embodiments of this aspect, the leukemia is refractory leukemia. In some embodiments of the foregoing embodiments, the refractory leukemia is associated with mutations in the Bcr-Abl tyrosine kinase gene that result in specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I. In a further embodiment of the foregoing embodiments, the refractory leukemia is associated with a mutation in the Bcr-Abl tyrosine kinase gene that results in the substitution of a specific amino acid, T315I. In other embodiments that can be combined with any of the foregoing embodiments of this aspect, the method further includes administration of one or more pharmaceutical agents, including anti-microtubule therapeutic agents, topoisomerase inhibitors, alkylating agents, nucleotide synthesis inhibitors, DNA synthesis inhibitors, protein synthesis inhibitors, developmental signaling pathway inhibitors, pro-apoptotic agents, Abl myristoyl-pocket binding inhibitors, MEK1 / 2 inhibitors, AKT inhibitors, PI3K inhibitors, and / or irradiation.

[0158] This application also includes the following implementation schemes.

[0159] 1. A compound of formula (I):

[0160]

[0161] Or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein:

[0162] X is NR 3’ or CR 3 ,

[0163] Y is NR 2 or CR 4 ,

[0164] Where X is NR 3’ When, then Y is CR 4 Y has up to CR 5 The double bond, and X has up to CR 5 A single bond; or when X is CR 3 When Y is NR 2 Y has up to CR 5 The single bond, and X has up to CR5 Double bonds;

[0165] R 0 as a group

[0166] m is an integer from 0 to 3;

[0167] Each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0168] R 2 It is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0169] R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN;

[0170] R 3’ It can be -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN;

[0171] R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0172] R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0173] R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4 to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0174] Each R 7 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0175] Each R 8 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0176] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein the heterocycles optionally contain 1 to 2 additional heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0177] Each R 9 Independent of halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl,

[0178] Where n is an integer from 0 to 2; and

[0179] Each R 10 Independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group and / or 1-6 deuterium atoms.

[0180] 2. A compound of formula (I):

[0181]

[0182] Or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein:

[0183] X is NR 3’ or CR 3 ,

[0184] Y is NR 2 or CR 4 ,

[0185] Where X is NR3’ When, then Y is CR 4 Y has up to CR 5 The double bond, and X has up to CR 5 A single bond; or when X is CR 3 When Y is NR 2 Y has up to CR 5 The single bond, and X has up to CR 5 Double bonds;

[0186] R 0 as a group

[0187] m is an integer from 0 to 3;

[0188] Each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0189] R 2 It is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0190] R 3It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN;

[0191] R 3’ It can be -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN;

[0192] R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0193] R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0194] R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0195] Each R 7 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0196] Each R 8 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0197] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0198] Each R 9 Independent of halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl,

[0199] Where n is an integer from 0 to 2; and

[0200] Each R 10 Independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group and / or 1-6 deuterium atoms.

[0201] 3. A compound as described in embodiment 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IA):

[0202]

[0203] 4. A compound as described in any one of embodiments 1 to 3, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IAi) or (IA-ii):

[0204]

[0205] in

[0206] m is an integer, either 0 or 2;

[0207] Each R 1 Independently -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene groups are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0208] R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3;

[0209] R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN;

[0210] R 3’ It can be -H, C1-C3 alkyl, C3-cycloalkyl or -CN;

[0211] R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen;

[0212] R 5 For C6-C 14 Aryl or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is selected from the group consisting of:

[0213]

[0214]

[0215] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0216] Each R 7 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0217] Each R 8 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0218] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0219] Each R 9 Independent of halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and

[0220] Each R 10 Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy and / or 1-6 deuterium atoms.

[0221] 5. The compound as described in any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0222] Each R 1 Independently -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH; and

[0223] Where R 1 Each pair of R 7’ and R 8’Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atoms of any primary or secondary amines present in the heterocycles are optionally substituted with -H or C1-C3 alkyl groups.

[0224] 6. The compound as described in any one of embodiments 1 to 5, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0225] R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0226]

[0227] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution.

[0228] 7. The compound as described in any one of embodiments 1 to 6, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0229] R 2 It can be -CH3, -CD3, or -CH2CH3;

[0230] R 3 -H, -F, -CH3, or -CN;

[0231] R 3’ It is -H or -CH3; and

[0232] R 4 It can be -H, -F, or -CH3.

[0233] 8. The compound as described in any one of embodiments 1 to 7, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0234] Each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN, and

[0235] Each R 10 Independently -H, -CH3, -CD3 or -CH2CH3, wherein the -CH3 or the -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3.

[0236] 9. A compound as described in any one of embodiments 1 to 8, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IAi) or (IA-ii):

[0237]

[0238] in

[0239] m is an integer, either 0 or 1;

[0240] R 1 -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH;

[0241] R 2 It can be -CH3, -CD3, or -CH2CH3;

[0242] R 3 -H, -F, -CH3, or -CN;

[0243] R 3’ -H or -CH3;

[0244] R 4 It can be -H, -F, or -CH3;

[0245] R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0246]

[0247] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution;

[0248] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atoms of any primary or secondary amine present in the heterocycles are optionally substituted with -H or C1-C3 alkyl groups.

[0249] Each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN, and

[0250] Each R 10Independently -H, -CH3, -CD3 or -CH2CH3, wherein the -CH3 or the -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3.

[0251] 10. A compound as described in any one of embodiments 1 to 9, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IAi) or (IA-ii):

[0252]

[0253] in

[0254] m is an integer, either 0 or 1;

[0255] R 1 -F;

[0256] R 2 -CH3;

[0257] R 3 -H or -CH3;

[0258] R 3’ -H or -CH3;

[0259] R 4 -CH3;

[0260] R 5 It is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0261]

[0262] The 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution;

[0263] Each R 9 Independent of -F or -OR 10 ,and

[0264] Each R 10 It can be -H or -CH3 independently.

[0265] 11. A compound as described in embodiment 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IB):

[0266]

[0267] 12. A compound as described in any one of embodiments 1, 2, and 11, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IBi) or (IB-ii):

[0268]

[0269] in

[0270] R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3;

[0271] R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN;

[0272] R 3’ It can be -H, C1-C3 alkyl, C3-cycloalkyl or -CN;

[0273] R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen;

[0274] R 5 For C6-C 14 Aryl or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is selected from the group consisting of:

[0275]

[0276] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0277] R 6 It is a C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0278] Each R 7 Independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0279] Each R 8 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0280] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0281] Each R 9 Independent of halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and

[0282] Each R 10 Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy.

[0283] 13. The compound as described in any one of embodiments 1 to 2 and 11 to 12, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0284] R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ ;and

[0285] Where R 6 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain 1 to 2 additional heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0286] 14. The compound as described in any one of embodiments 1 to 2 and 11 to 13, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0287] R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0288]

[0289] The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution.

[0290] 15. The compound as described in any one of embodiments 1 to 2 and 11 to 14, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0291] Each R 9 Independently -F, -OR 10 Or -CH3, and

[0292] Each R 10 It can be -H, -CH3, -CD3, -CF2H or -CF3 independently.

[0293] 16. The compound as described in any one of embodiments 1 to 2 and 11 to 15, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein

[0294] R 2 -H or -CH3;

[0295] R 3 -H;

[0296] R3’ It is -H; and

[0297] R 4 It can be -H or -CH3.

[0298] 17. A compound as described in any one of embodiments 1 to 2 and 11 to 16, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the compound of formula (I) is a compound of formula (IBi) or formula (IB-ii):

[0299]

[0300] in

[0301] R 2 -H or -CH3;

[0302] R 3 -H;

[0303] R 3’ -H;

[0304] R 4 -H or -CH3;

[0305] R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution;

[0306] R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ ;

[0307] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0308] Each R 9 Independently -F, -OR 10 Or -CH3, and

[0309] Each R 10 It can be -H, -CH3, -CD3, -CF2H or -CF3 independently.

[0310] 18. A compound selected from the group consisting of:

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322] Or a pharmaceutically acceptable salt, solvate, hydrate or eutectic, or a mixture of any of the foregoing substances.

[0323] 19. A compound selected from the group consisting of:

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336] Or a pharmaceutically acceptable salt, solvate, hydrate or eutectic, or a mixture of any of the foregoing substances.

[0337] 20. A pharmaceutical composition comprising a compound as described in any one of embodiments 1 to 19, or a pharmaceutically acceptable salt, solvate, hydrate or eutectic thereof, or a mixture of any of the foregoing substances, and one or more pharmaceutically acceptable excipients.

[0338] 21. A method for inhibiting the enzymatic activity of Bcr-Abl in cells, comprising exposing the cells to an effective amount of a compound as described in any one of embodiments 1 to 19, or a pharmaceutically acceptable salt, solvate, hydrate or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition as described in embodiment 20.

[0339] 22. A method of treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia in a person in need, comprising administering to the person a compound as described in any one of embodiments 1 to 19, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition as described in embodiment 20.

[0340] 23. The method as described in embodiment 22, wherein the leukemia is a refractory leukemia.

[0341] 24. The method of embodiment 23, wherein the refractory leukemia is associated with a mutation in the Bcr-Abl tyrosine kinase gene that results in a specific amino acid substitution selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

[0342] 25. The method of embodiment 24, wherein the refractory leukemia is associated with a mutation in the Bcr-Abl tyrosine kinase gene that results in the substitution of a specific amino acid, T315I.

[0343] 26. The method of embodiment 23, wherein the person suffering from refractory leukemia has one or more mutations in the Bcr-Abl tyrosine kinase gene that result in a specific amino acid substitution selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

[0344] 27. The method of embodiment 26, wherein the person suffering from refractory leukemia has a mutation in the Bcr-Abl tyrosine kinase gene that results in the substitution of a specific amino acid, T315I.

[0345] 28. The method of any one of embodiments 21 to 27, further comprising administering one or more pharmaceutical agents, said pharmaceutical agents including antimicrotubule therapeutic agents, topoisomerase inhibitors, alkylating agents, nucleotide synthesis inhibitors, DNA synthesis inhibitors, protein synthesis inhibitors, developmental signaling pathway inhibitors, pro-apoptotic agents, Abl myristoyl-pocket binding inhibitors, MEK1 / 2 inhibitors, AKT inhibitors, PI3K inhibitors, and / or irradiation. Detailed Implementation

[0346] The following description illustrates exemplary methods, parameters, etc. However, it should be understood that this description is not intended to limit the scope of this disclosure, but is provided as a description of exemplary embodiments.

[0347] I. Definition

[0348] As used herein, unless otherwise stated, the following definitions shall apply. Furthermore, if any term or symbol used herein is not defined as described below, it shall have its ordinary meaning in the art.

[0349] As used herein, the term "excipient" means an inert or inactive substance that can be used to produce a drug or pharmaceutical preparation, such as a tablet containing a compound of the present disclosure as an active ingredient. The term "excipient" can include a variety of substances, including but not limited to any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, parenteral solution, chewable tablet material, sweetener or flavoring agent, suspending / gelling agent, or wet granulation agent. Binders include, for example, carbomer, povidone, xanthan gum, etc.; coatings include, for example, cellulose acetate phthalate, ethyl cellulose, gellan gum, maltodextrin, enteric coating, etc.; compression / encapsulation aids include, for example, calcium carbonate, glucose, fructose DC (DC = "directly compressible"), honey DC, lactose (anhydrous or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch DC, sucrose, etc.; disintegrants include, for example, sodium croscarmellose, gellan gum, etc. Sodium starch glycolate, etc.; creams or lotions including, for example, maltodextrin, carrageenan, etc.; lubricants including, for example, magnesium stearate, stearic acid, sodium stearoyl fumarate, etc.; chewable tablet materials including, for example, glucose, fructose DC, lactose (monohydrate, optionally combined with aspartame or cellulose), etc.; suspending / gelling agents including, for example, carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners including, for example, aspartame, glucose, fructose DC, sorbitol, sucrose DC, etc.; and wet granulation agents including, for example, calcium carbonate, maltodextrin, microcrystalline cellulose, etc.

[0350] The terms “individual,” “subject,” and “patient” refer to mammals and include both human and non-human mammals. Examples of patients include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cattle, and humans. In some implementations, a patient refers to a human.

[0351] As used herein, the term “mammal” includes, but is not limited to, humans, mice, rats, guinea pigs, monkeys, dogs, cats, horses, cattle, pigs, and sheep.

[0352] "Pharmaceutical acceptable" means safe and non-toxic, and suitable for internal or human use.

[0353] As used herein, unless otherwise stated, the term "alkyl" on its own or as part of another substituent means a straight-chain or branched hydrocarbon group having a specified number of carbon atoms (e.g., C1-C6 means 1 to 6 carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, etc. In some embodiments, the term "alkyl" may cover C1-C6 alkyl, C2-C6 alkyl, C3-C6 alkyl, C4-C6 alkyl, C5-C6 alkyl, C1-C5 alkyl, C2-C5 alkyl, C3-C5 alkyl, C4-C5 alkyl, C1-C4 alkyl, C2-C4 alkyl, C3-C4 alkyl, C1-C3 alkyl, C2-C3 alkyl, or C1-C2 alkyl.

[0354] The terms “cycloalkyl,” “carbocyclic,” or “carbocyclic” refer to a hydrocarbon ring having an indicated number of ring atoms (e.g., C3-C6 cycloalkyl means 3-6 carbons) and being fully saturated or having no more than one double bond between the ring vertices. As used herein, “cycloalkyl,” “carbocyclic,” or “carbocyclic” also mean bicyclic, polycyclic, and spirocyclic hydrocarbon rings, such as bicyclic [2.2.1]heptane, pinane, bicyclic [2.2.2]octane, adamantane, norbornene, and spirocyclic C… 5-12 Alkanes, etc. In some embodiments, "cycloalkyl" encompasses C3-C7 cycloalkyl, C4-C7 cycloalkyl, C5-C7 cycloalkyl, C5-C7 cycloalkyl, C3-C6 cycloalkyl, C4-C6 cycloalkyl, C5-C6 cycloalkyl, C3-C5 cycloalkyl, C4-C5 cycloalkyl, or C3-C4 cycloalkyl. Furthermore, one ring of a polycyclic cycloalkyl group may be aromatic, provided that the polycyclic cycloalkyl group is bonded to the parent structure via a non-aromatic carbon atom. For example, 1,2,3,4-tetrahydronaphth-1-yl (wherein the moiety is bonded to the parent structure via a non-aromatic carbon atom) is a cycloalkyl group, while 1,2,3,4-tetrahydronaphth-5-yl (wherein the moiety is bonded to the parent structure via an aromatic carbon atom) is not considered a cycloalkyl group.

[0355] Unless otherwise stated, the term "heteroalkyl" on its own or in combination with another term means a stable straight-chain or branched hydrocarbon group consisting of a specified number of carbon atoms and one to three heteroatoms selected from the group consisting of O, N, Si, and S, wherein nitrogen and sulfur atoms may optionally be oxidized, and nitrogen heteroatoms may optionally be quaternized. Heteroatoms O, N, and S may be placed in any internal position of the heteroalkyl group. Heteroatoms Si may be placed in any position of the heteroalkyl group, including positions where alkyl fluoride is attached to the remainder of the molecule. "Heteroalkyl" may contain up to three unsaturated units and also includes monohalogenated and polyhalogenated variants, or combinations thereof. Examples include -CH2-CH2-O-CH3, -CH2-CH2-O-CF3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH═CH-O-CH3, -Si(CH3)3, -CH2-CH═N-OCH3, and -CH═CH═N(CH3)-CH3. Up to two heteroatoms can be consecutive, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3.

[0356] The terms "heterocyclic alkyl," "heterocyclic," or "heterocyclic" refer to a cycloalkyl group (e.g., 5-6 membered heterocyclic alkyl) having an indicated number of ring atoms, containing 1-5 heteroatoms selected from the group consisting of N, O, and S as ring atoms, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. Unless otherwise stated, the "heterocyclic alkyl," "heterocyclic," or "heterocyclic" ring can be monocyclic, bicyclic, bridged, fused, spirocyclic, or polycyclic. Non-limiting examples of "heterocyclic alkyl", "heterocyclic", or "heterocyclic" rings include pyrrolidine, piperidine, N-methylpiperidine, imidazoline, pyrazolidine, butyrolactam, valproic acid, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidine-2,4(1H,3H)-dione, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-5-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrrolidine, thiaran, pyranone, tetrahydrofuran, tetrahydrothiophene, quinine ring, and scopolamine. A "heterocyclic alkyl", "heterocyclic", or "heterocyclic" group can be attached to the remainder of the molecule via one or more cyclic carbons or heteroatoms. In some embodiments, "heterocyclic alkyl" includes 3- to 10-membered heterocyclic alkyl, 4- to 10-membered heterocyclic alkyl, 5- to 10-membered heterocyclic alkyl, 6- to 10-membered heterocyclic alkyl, 7- to 10-membered heterocyclic alkyl, 8- to 10-membered heterocyclic alkyl, 9- to 10-membered heterocyclic alkyl, 3- to 9-membered heterocyclic alkyl, 4- to 9-membered heterocyclic alkyl, 5- to 9-membered heterocyclic alkyl, 6- to 9-membered heterocyclic alkyl, 7- to 9-membered heterocyclic alkyl, 8- to 9-membered heterocyclic alkyl, 3- to 8-membered heterocyclic alkyl, 4- to 8-membered heterocyclic alkyl, 5- to 8-membered heterocyclic alkyl, 6- to 8-membered heterocyclic alkyl, 7- to 8-membered heterocyclic alkyl, 3- to 7-membered heterocyclic alkyl, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkyl, 6- to 7-membered heterocyclic alkyl, 3- to 6-membered heterocyclic alkyl, 4- to 6-membered heterocyclic alkyl, 5- to 6-membered heterocyclic alkyl, 3- to 10-membered heterocyclic alkyl, 4- to 5-membered heterocyclic alkyl, or 3- to 4-membered heterocyclic alkyl. In other embodiments, "heterocyclic alkyl" can be characterized by the number of carbon atoms in the ring, provided that the ring contains at least one heteroatom. For example, in some embodiments, "heterocyclic alkyl" encompasses C3-C9 heterocyclic alkyl, C3-C8 heterocyclic alkyl, C3-C7 heterocyclic alkyl, C3-C6 heterocyclic alkyl, C3-C5 heterocyclic alkyl, C3-C4 heterocyclic alkyl, C4-C9 heterocyclic alkyl, C4-C8 heterocyclic alkyl, C4-C7 heterocyclic alkyl, C4-C6 heterocyclic alkyl, C4-C5 heterocyclic alkyl, C5-C9 heterocyclic alkyl, C5-C8 heterocyclic alkyl, C5-C7 heterocyclic alkyl, C5-C6 heterocyclic alkyl, C6-C9 heterocyclic alkyl, C6-C8 heterocyclic alkyl, C6-C7 heterocyclic alkyl, C7-C9 heterocyclic alkyl, C7-C8 heterocyclic alkyl, or C8-C9 heterocyclic alkyl. It should be recognized that "heterocyclic alkyl" as described in terms of the number of ring atoms can also be described in terms of the number of carbon atoms in the ring.For example, a piperazine ring can be described as a C4 heterocyclic alkyl ring or a 6-membered heterocyclic alkyl ring; an nitrogen-containing heterocyclic butyl ring or an oxocyclic butyl ring can each be described as a C3 heterocyclic alkyl ring or a 4-membered heterocyclic alkyl ring.

[0357] The term "alkylene" itself, or as part of another substituent, refers to a divalent group derived from an alkane, such as that exemplified by -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group has 1 to 24 carbon atoms. In some embodiments, the alkyl (or alkylene) group will have 10 or fewer carbon atoms.

[0358] The term "heteroalkylene" itself, or as part of another substituent, refers to a saturated, unsaturated, or polyunsaturated divalent group derived from a heteroalkyl group, such as those exemplified by -CH2-CH2-S-CH2CH2-, -CH2-S-CH2-CH2-NH-CH2-, -O-CH2-CH═CH-, -CH2-CH═C(H)CH2-O-CH2-, and -S-CH2-C≡C-. For heteroalkylene groups, the heteroatom can also occupy any one or both chain ends (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.).

[0359] The term "heterocyclic alkyl" itself, or as part of another substituent, refers to a saturated, unsaturated, or polyunsaturated divalent group derived from a heterocyclic alkyl group. For heterocyclic alkyl groups, heteroatoms may also occupy any one or both chain ends.

[0360] The terms “alkoxy” and “alkylamino” are used in their conventional sense and refer to those alkyl groups that are attached to the rest of the molecule by an oxygen atom or an amino group, respectively.

[0361] The term “heterocyclic alkoxy” refers to a heterocyclic alkyl-O- group, wherein the heterocyclic alkyl group is as described above in this article.

[0362] Unless otherwise stated, the terms "halogenated" or "halogen" mean, either on their own or as part of another substituent, a fluorine, chlorine, bromine, or iodine atom. Additionally, the term "halogenated alkyl" is intended to include both monohalogenated and polyhalogenated alkyl groups. For example, the term "C1-C4 haloalkyl" is intended to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, difluoromethyl, etc.

[0363] The term "haloalkyl-OH" refers to a haloalkyl group that is also substituted with one or more hydroxyl groups, as described above. The term "haloalkyl-OH" is intended to include haloalkyl groups substituted with one hydroxyl group, as well as haloalkyl groups substituted with multiple hydroxyl groups. For example, the term "haloalkyl-OH" includes -CH(F)OH, -CH2CFHCH2OH, -CH(OH)CF3, etc.

[0364] The term "alkyl-OH" refers to an alkyl group substituted with one or more hydroxyl groups. The term "alkyl-OH" is intended to include alkyl groups substituted with one hydroxyl group, as well as alkyl groups substituted with multiple hydroxyl groups. For example, the term "alkyl-OH" includes -CH2OH, -CH(OH)CH3, -CH2CH2OH, -C(CH3)2OH, etc.

[0365] The term "alkyl-CN" refers to an alkyl group substituted with one or more cyano groups. The term "alkyl-CN" is intended to include alkyl groups substituted with one cyano group, as well as alkyl groups substituted with multiple cyano groups. For example, the term "alkyl-CN" includes -CH2CN, -CH2CH2CN, -CH(CN)CH3, etc.

[0366] Unless otherwise stated, the term "aryl" refers to a polyunsaturated, typically aromatic, hydrocarbon group, which can be a single ring or multiple rings fused together (up to three rings). In some embodiments, "aryl" includes C6-C 14 Aryl, C8-C 14 Aryl, C 10 -C 14 Aryl, C 12 -C 14 Aryl, C6-C 12 Aryl, C8-C 12 Aryl, C 10 -C 12 Aryl, C6-C 10 Aryl, C8-C 10 Aryl or C6-C8 aryl. In some embodiments, both rings of the polycyclic aryl group are aromatic (e.g., naphthyl). In other embodiments, the polycyclic aryl group may include a non-aromatic ring fused to an aromatic ring, provided that the polycyclic aryl group is bonded to the parent structure via an atom in the aromatic ring. Thus, in some embodiments, 1,2,3,4-tetrahydronaphth-5-yl (wherein the portion is bonded to the parent structure via a non-aromatic carbon atom) is considered an aryl group, while 1,2,3,4-tetrahydronaphth-1-yl (wherein the portion is bonded to the parent structure via a non-aromatic carbon atom) is not considered an aryl group. Similarly, in some embodiments, 1,2,3,4-tetrahydroquinoline-8-yl (wherein the portion is bonded to the parent structure via an aromatic carbon atom) is considered an aryl group, while 1,2,3,4-tetrahydroquinoline-1-yl (wherein the portion is bonded to the parent structure via a non-aromatic nitrogen atom) is not considered an aryl group. However, the term "aryl" does not encompass or overlap with "heteroaryl" as defined herein, regardless of the attachment point (e.g., quinoline-5-yl and quinoline-2-yl are both heteroaryls). In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl group is phenyl.

[0367] The term "heteroaryl" refers to an aryl group (or ring) containing one to five heteroatoms selected from the group consisting of N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. Where valence permits, the heteroaryl group can be attached to the remainder of the molecule via carbon or heteroatoms. In some embodiments, both rings of the polycyclic heteroaryl group are aromatic. In other embodiments, the polycyclic heteroaryl group may include a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocyclic alkyl, heterocyclic alkenyl) fused to the heteroaryl ring, provided that the polycyclic heteroaryl group is bonded to the parent structure via atoms in the aromatic ring. For example, in some embodiments, 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl (wherein the portion is bonded to the parent structure via an aromatic carbon atom) is considered a heteroaryl group, while 4,5,6,7-tetrahydrobenzo[d]thiazol-5-yl (wherein the portion is bonded to the parent structure via a non-aromatic carbon atom) is not considered a heteroaryl group.

[0368] Non-limiting examples of aryl groups include phenyl, naphthyl, and biphenyl, while non-limiting examples of heteroaryl groups include pyridyl, pyrazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cyclophosphinyl, phthalazinyl, benzotriazinyl, purineyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzoisoazolyl, isobenzofuranyl, isoindolyl, indolazinyl, benzotriazinyl, thienopyridyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazonopyridyl, benzothiazolyl, benzofuranyl, benzothiaphenyl, indolyl, quinolinyl, isoquinolinyl, isothiazolyl, pyrazolyl, inazolyl, pteridinyl, imidazoleyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrroleyl, thiazolyl, furanyl, thiopheneyl, etc. In some implementations, the term "heteroaryl" encompasses 5- to 10-membered heteroaryl, 6- to 10-membered heteroaryl, 7- to 10-membered heteroaryl, 8- to 10-membered heteroaryl, 9- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, 6- to 9-membered heteroaryl, 7- to 9-membered heteroaryl, 8- to 9-membered heteroaryl, 5- to 8-membered heteroaryl, 6- to 8-membered heteroaryl, 7- to 8-membered heteroaryl, 5- to 7-membered heteroaryl, 6- to 7-membered heteroaryl, or 5- to 6-membered heteroaryl.

[0369] In some embodiments, the terms above (e.g., "alkyl", "aryl", and "heteroaryl") will include both substituted and unsubstituted forms of the indicated group. The term "substituted" means that the specified group or portion contains one or more substituents, including but not limited to substituents such as: alkoxy, acyl, acyloxy, alkoxycarbonyl, carbonylalkoxy, amide, amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, cycloalkyl, cycloalkenyl, aryl, heteroaryl, aryloxy, cyano, azide, halogen, hydroxyl, nitro, carboxyl, thiol, thioalkyl, alkyl, alkenyl, alkynyl, heterocyclic alkyl, heterocyclic alkenyl, aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, etc. The term "unsubstituted" means that the specified group does not contain any substituents. When the term "substituted" is used to describe a structural system, substitution is intended to occur at any position allowed by the valence in the system. When a group or portion contains more than one substituent, it should be understood that the substituents may be the same as or different from each other. In some embodiments, the substituted group or portion has one to five substituents. In some embodiments, the substituted group or portion has one substituent. In some embodiments, the substituted group or portion has two substituents. In some embodiments, the substituted group or portion has three substituents. In some embodiments, the substituted group or portion has four substituents. In some embodiments, the substituted group or portion has five substituents.

[0370] "Optional" or "optionally" means that the event or situation described below may or may not occur, and the description includes examples of both the occurrence and non-occurrence of the event or situation. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. Those skilled in the art will understand that for any group containing one or more substituents, such groups are not intended to introduce any substitution or substitution pattern that is spatially impractical, synthetically infeasible, and / or inherently unstable. It should also be understood that, where a group or portion is optionally substituted, this disclosure includes embodiments in which the group or portion is substituted and embodiments in which the group or portion is not substituted.

[0371] As used in this article, the term “heteroatoms” is intended to include oxygen (O), nitrogen (N), sulfur (S), and silicon (Si).

[0372] As used herein, the term "chirality" refers to a molecule that has the property that its mirror-pairs cannot overlap, while the term "chirality" refers to a molecule that can overlap its mirror-pairs.

[0373] As used herein, the term “stereoisomer” refers to compounds that have the same chemical composition but differ in the spatial arrangement of atoms or groups.

[0374] As used in this article, the wavy lines intersecting with bonds in the chemical structure Indicates the attachment point of an atom connected by a wavy bond to the rest of the molecule or to the rest of a molecular segment in a chemical structure.

[0375] As used in this article, the groups in parentheses (e.g., X) a () followed by an integer range of subscripts (e.g., (X) a ) 0-1 The ) symbol indicates that the group can have an integer number of occurrences. For example, (X a ) 0-1 Indicator group X a It may not exist or it may appear once.

[0376] "Diabeta-isomers" are stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diabeta-isomers have different physical properties, such as melting point, boiling point, spectral characteristics, and reactivity. Mixtures of diastereomers can be separated using high-resolution analytical procedures such as electrophoresis and chromatography.

[0377] "Enantiomers" refer to two stereoisomers of a compound that are non-overlapping mirror images of each other.

[0378] The stereochemical definitions and conventions used herein generally follow those of SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984), McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. The compounds of this disclosure may contain asymmetric or chiral centers and thus exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of this disclosure, including but not limited to diastereomers, enantiomers, and transisomers, and mixtures thereof such as racemic mixtures, form part of this disclosure. Many organic compounds exist in optically active forms, i.e., they are capable of rotating the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule with respect to its chiral center. The prefixes d and l, or (+) and (-), are used to indicate the optical rotation of a compound with respect to plane-polarized light, where (-) or l indicates that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers can also be called enantiomers, and mixtures of such isomers are often called enantiomeric mixtures. A 50:50 enantiomeric mixture is called a racemic mixture or racemate, which can occur when stereoselectivity or stereospecificity is not yet present in the chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two optically inactive enantiomer species.

[0379] As used herein, the terms "tautomer" or "tautomer form" refer to structural isomers of different energies that can interconvert via low energy barriers. For example, proton tautomers (also known as proton transfer tautomers) include interconversions via proton transfer, such as keto-enol and imine-enamine isomerization. Valence tautomers include interconversions via some recombination of bonding electrons.

[0380] As used herein, the term "solvent" refers to an association or complex of one or more solvent molecules and a compound of this disclosure. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex in which the solvent molecule is water. Certain compounds of this disclosure may exist in both unsolvated and solvated forms (including hydrated forms). Generally, solvated forms are equivalent to unsolvated forms and are intended to be covered within the scope of this disclosure.

[0381] As used herein, the term "eutectic" refers to a solid, which is a crystalline single-phase material composed of two or more distinct molecular or ionic compounds typically in stoichiometric ratios, said compounds being neither solvates nor simple salts. A eutectic consists of two or more components that form a unique crystal structure with distinctive properties. Eutectics are typically characterized by a crystalline structure, usually bonded together by free, reversible, non-covalent interactions. As used herein, a eutectic refers to the compounds of this disclosure and at least one other component forming a crystalline structure in a defined stoichiometric ratio.

[0382] As used herein, the term "protecting group" refers to a substituent commonly used to block or protect a specific functional group on a compound. For example, an "amino protecting group" is a substituent attached to an amino group to block or protect the amino functionality in a compound. Suitable amino protecting groups include acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), and 9-fluorenylmethoxycarbonyl (Fmoc). Similarly, a "hydroxyl protecting group" refers to a hydroxyl substituent that blocks or protects the hydroxyl functionality. Suitable protecting groups include acetyl and silyl. A "carboxyl protecting group" refers to a carboxyl substituent that blocks or protects the carboxyl functionality. Common carboxyl protecting groups include benzenesulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrosulfinyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl, etc. For a general description of protecting groups and their uses, see PGMWuts and TWGreene, Greene's Protective Groups in Organic Synthesis, 4th Edition, Wiley-Interscience, New York, 2006.

[0383] As used herein, the term "pharmaceutically acceptable salt" is intended to include salts of active compounds prepared with relatively non-toxic acids or bases based on specific substituents present on the compounds described herein. When the compounds of this disclosure contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either pure or in a suitable inert solvent. Examples of salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, iron, ferrous, lithium, magnesium, manganese, manganese, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines, including substituted amines, cyclic amines, and naturally occurring amines, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hepatic acid, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc. When the compounds of this disclosure contain relatively basic functional groups, acid addition salts can be obtained by contacting such compounds in neutral form with a sufficient amount of the desired acid purely or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrocarbonic acid, phosphoric acid, phosphoric acid monohydrogen phosphate, phosphoric acid dihydrogen phosphate, sulfuric acid, hydrosulfuric acid, hydroiodic acid, or phosphorous acid; and salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, malonic acid, benzoic acid, succinic acid, succinic acid, fumaric acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid. Also included are salts of amino acids, such as arginine salts; and salts of organic acids, such as glucuronic acid or galacturonic acid (see, for example, Berge, SM et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds disclosed herein contain basic and acidic functional groups that allow the compounds to be converted into base addition salts or acid addition salts.

[0384] The neutral form of a compound can be regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in some physical properties (such as solubility in polar solvents), but for the purposes of this disclosure, these salts are equivalent to the parent form of the compound.

[0385] Some compounds disclosed herein have asymmetric carbon atoms (optical centers) or double bonds; racemates, diastereomers, geometric isomers, regioisomers and single isomers (e.g., individual enantiomers) are all intended to be covered within the scope of this disclosure.

[0386] The compounds of this disclosure may also contain atomic isotopes in non-natural proportions at one or more atoms constituting such compounds. For example, this disclosure also includes variations of the isotopic designation of this disclosure that are identical to those variations of the coefficients herein, but in fact, one or more atoms are replaced by atoms with atomic masses or mass numbers different from the principal atomic masses or mass numbers normally found in nature. All isotopes of any particular atom or element specified are considered within the scope of the compounds of this disclosure and include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as... 2 H(“D”), 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 32 P, 33 P, 35 S, 18 F, 36 Cl、 123 I and 125 I. Certain isotopically labeled compounds of this disclosure (e.g., those labeled with...) 3 H or 14 Those labeled with C can be used for the determination of the tissue distribution of compounds and / or substrates. Tritium ( 3 H) and carbon-14 ( 14 C) Isotopes are useful due to their ease of preparation and detectability. Further, heavier isotopes such as deuterium (i.e.,...) are used. 2 H) substitution can provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life and reduced dose requirements), and is therefore preferred in some cases. Positron-emitting isotopes such as 15 O、 13 N、 11 C and 18 F can be used in positron emission tomography (PET) studies to examine substrate acceptor occupancy. The isotopically labeled compounds of this disclosure can generally be prepared by replacing non-isotopically labeled reagents with isotopically labeled reagents using procedures similar to those disclosed in the schemes and / or examples below.

[0387] "Treatment" in the context of a patient's disease refers to suppressing or preventing the progression of the disease; or improving or causing its remission. As used herein, "treatment" is a method for achieving beneficial or desired outcomes (including clinical outcomes). For the purposes of this disclosure, beneficial or desired outcomes include, but are not limited to, one or more of the following: reducing one or more symptoms caused by the disease or condition; alleviating the severity of the disease or condition; stabilizing the disease or condition (e.g., preventing or delaying the worsening of the disease or condition); delaying the onset or recurrence of the disease or condition; delaying or slowing the progression of the disease or condition; improving the state of the disease or condition; providing remission (partial or complete remission) of the disease or condition; reducing the dosage of one or more other medications required to treat the disease or condition; enhancing the effect of another medication used to treat the disease or condition; delaying the progression of the disease or condition; improving quality of life; and / or prolonging patient survival. "Treatment" also includes the alleviation of pathological outcomes of the disease or condition. The methods of this disclosure consider any or more of these aspects of treatment.

[0388] "Prevention" or "treatment" of a patient's disease refers to preventing the disease from developing in patients who are susceptible to it or who have not yet shown symptoms of the disease.

[0389] The phrase “therapeutic effective amount” means that the compounds disclosed herein are used in amounts that: (i) treat or prevent a particular disease, symptom or condition; (ii) reduce, improve or eliminate one or more symptoms of a particular disease, symptom or condition; or (iii) prevent or delay the onset of one or more symptoms of a particular disease, symptom or condition described herein.

[0390] The terms “cancer” and “carcinoma” refer to or describe a physiological condition in mammals that is typically characterized by unregulated cell growth.

[0391] It should be understood that certain features of this disclosure described in the context of individual embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of individual embodiments for brevity may also be provided individually or in any suitable sub-combination. All combinations of embodiments belonging to chemical groups represented by variables are specifically included in the invention and disclosed herein as if each combination were individually and explicitly disclosed, to the extent that such combinations encompass compounds that are stable compounds (i.e., compounds whose biological activity can be isolated, characterized, and tested). Additionally, all sub-combinations of chemical groups listed in embodiments describing such variables are also specifically included in the invention and disclosed herein as if each sub-combination of chemical groups were individually and explicitly disclosed herein.

[0392] II.Compounds

[0393] On the one hand, this paper provides a compound of formula (I),

[0394]

[0396] Or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein:

[0397] X is NR 3’ or CR 3 ,

[0398] Y is NR 2 or CR 4 ,

[0399] Where X is NR 3’ When, then Y is CR 4 Y has up to CR 5 The double bond, and X has up to CR 5 A single bond; or when X is CR 3 When Y is NR 2 Y has up to CR 5 The single bond, and X has up to CR 5 Double bonds;

[0400] R 0 as a group

[0401] m is an integer from 0 to 3;

[0402] Each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0403] R 2 It is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0404] R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN;

[0405] R 3’ It can be -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN;

[0406] R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0407] R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0408] R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4 to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0409] Each R 7 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0410] Each R 8 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0411] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein the heterocycles optionally contain 1 to 2 additional heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0412] Each R 9 Independent of halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl,

[0413] Where n is an integer from 0 to 2; and

[0414] Each R 10 Independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group and / or 1-6 deuterium atoms.

[0415] On the one hand, this paper provides a compound of formula (I).

[0416]

[0417] Or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein:

[0418] X is NR 3’ or CR 3 ,

[0419] Y is NR 2 or CR 4 ,

[0420] Where X is NR 3’ When, then Y is CR 4 Y has up to CR 5 The double bond, and X has up to CR 5 A single bond; or when X is CR 3 When Y is NR 2 Y has up to CR 5 The single bond, and X has up to CR 5 Double bonds;

[0421] R 0 as a group

[0422] m is an integer from 0 to 3;

[0423] Each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0424] R 2 It is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0425] R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN;

[0426] R 3’ It can be -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN;

[0427] R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms;

[0428] R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0429] R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0430] Each R 7 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0431] Each R 8 Independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;

[0432] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0433] Each R 9 Independent of halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl,

[0434] Where n is an integer from 0 to 2; and

[0435] Each R10 Independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group and / or 1-6 deuterium atoms.

[0436] In some implementations of this aspect, R 0 for In which R 0 for In some implementations, m is an integer 0, 1, 2, or 3. In some implementations, m is 0. In other implementations, m is 1. In still other implementations, m is 2. In still other implementations, m is 3. In other implementations of this aspect, R 0 for

[0437] In some embodiments, the compound of formula (I) is a compound of formula (IA) or formula (IB):

[0438]

[0439] In some implementations, each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0440] In some implementations, each R 1 Independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, each R 1 Independently -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene groups are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, each R 1 Independently -D, -F, C1-C3 alkyl. In some embodiments, each R 1 Independently C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH or C1-C3 alkylene-CN. In some embodiments, each R 1 Independently C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ In some implementations, each R 1 Independently C1-C3 alkylene-NR7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ In some implementations, each R 1 Independently, it is C1-C3 alkylene-OH, C1-C3 alkylene-CN, or C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH. In some embodiments, each R 1 Independently -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH, wherein R 1 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, each R 1 Independently -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH, wherein R 1 Each pair of R 7’ and R 8’ They independently form 4- to 6-membered heterocycles together with the nitrogen atoms to which they are attached, wherein the heterocycles optionally contain an additional 1-2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atom of any primary or secondary amine present in the heterocycle is optionally substituted with H or a C1-C3 alkyl group. In some embodiments, each R 1 Independently -F, C1-C3 alkylene-NR 7 'R 8 'or C1-C3 alkylene-OH.' In some embodiments, each R 1For -F. In some implementations, each R 1 Independently C1-C3 alkylene-NR 7’ R 8’ In some implementations, each R 1 Independently, it is either an optionally substituted -C1-C2 alkylene-N-morpholino or an optionally substituted -C1-C2 alkylene-N-piperazino. In some embodiments, each R 1 Independently as an optional replacement Optional replacement Optional replacement Optional replacement Optional replacement Or optional replacement In some implementations, each R 1 Independently as an optional replacement Optional replacement Optional replacement Or optional replacement In some implementations, each R 1 Independently

[0441] In some implementations, each R 1 Independently In some other implementations, each R 1 Independently In other implementation schemes, each R 1 Independently In some implementations, each R 1 Independently, it is a C1-C3 alkylene-OH. In some other embodiments, each R 1 Independently -C1-C2 alkylene-OH. In some embodiments, each R 1 Independently, it is -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, -CH2CH(OH)CH3, or -CH(CN)CH2CH3. In some other embodiments, each R 1 It can be -CH2OH or -CH2CH2OH independently.

[0442] In some implementations of this aspect, X is CR 3 And Y is NR 2 In which X is CR 3 And Y is NR 2 In some implementation schemes, R 2It is -H, C1-C3 alkyl, or C3-C6 cycloalkyl, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN.

[0443] In some implementation schemes, R 2 It is -H, C1-C3 alkyl, or C3-C6 cycloalkyl, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 2 It is an -H or C1-C3 alkyl group, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 2 It is -H or C3-C6 cycloalkyl. In some embodiments, R 2 It is a C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 2 For -H. In some implementations, R 2 It is a C1-C3 alkyl group, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 2 The derivative is -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2, wherein the -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2 is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 2 It is a C3-C6 cycloalkyl group. In some embodiments, R 2 It is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

[0444] In some implementation schemes, R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3. In some implementations, R 2 It can be -CH3, -CD3, -CHF2, or -CH2CH3. In some implementations, R 2 It can be -H, -CD3, -CHF2, or -CH2CH3. In some implementations, R 2 It can be -H, -CH3, -CHF2, or -CH2CH3. In some implementations, R 2 It can be -H, -CH3, -CD3, or -CH2CH3. In some implementations, R 2 It can be -H, -CH3, -CD3, or -CHF2. In some implementations, R 2It is -CH3, -CD3, or -CHF2. In some implementations, R 2 It is -CH3 or -CH2CH3. In some implementations, R 2 It can be -H or -CH3.

[0445] In some implementation schemes, R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN. In some embodiments, R 3 It is -H, C1-C3 alkyl, C3-C6 cycloalkyl, or halogen. In some embodiments, R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, or -CN. In some embodiments, R 3 It can be -H, C1-C3 alkyl, halogen, or -CN. In some embodiments, R 3 It can be -H, C3-C6 cycloalkyl, halogen, or -CN. In some embodiments, R 3 It is a C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN. In some embodiments, R 3 It can be -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or -CN. In some embodiments, R 3 It can be -H, -F, -CH3, or -CN. In some implementations, R 3 It can be -H, -F, or -CH3. In some implementations, R 3 It can be -H, -F, or -CN. In some implementations, R 3 It can be -H, -CH3, or -CN. In some implementations, R 3 It can be -F, -CH3, or -CN. In some implementations, R 3 It is either -H or -F. In some implementations, R 3 It is -H or -CH3. In some implementations, R 3 It is either -H or -CN. In some implementations, R 3 For -F or -CH3. In some implementations, R 3 For -F or -CN. In some implementations, R 3 It is either -CH3 or -CN. In some implementations, R 3 For -H. In some implementations, R 3 For -F. In some implementations, R 3 For -CH3. In some implementations, R 3 For -CN.

[0446] In some implementation schemes, R 2 It is -CH3, -CD3, or -CH2CH3, and R3 It can be -H, -F, -CH3, or -CN. In some implementations, R 2 It is -CH3, and R 3 It can be -H, -F, -CH3, or -CN. In some implementations, R 2 It is -CD3, and R 3 It can be -H, -F, -CH3, or -CN. In some implementations, R 2 It is -CH2CH3, and R 3 It can be -H, -F, -CH3, or -CN. In some implementations, R 2 It is -CH3, -CD3, or -CH2CH3, and R 3 For -H. In some implementations, R 2 It is -CH3, -CD3, or -CH2CH3, and R 3 For -F. In some implementations, R 2 It is -CH3, -CD3, or -CH2CH3, and R 3 For -CH3. In some implementations, R 2 It is -CH3, -CD3, or -CH2CH3, and R 3 For -CN. In some implementations, R 2 It is -CH3, -CD3, or -CH2CH3, and R 3 It can be -H, -F, -CH3, or -CN. In some implementations, R 2 It is -CH3, and R 3 It is -H or -CH3. In some implementations, R 2 It is -CH3, and R 3 For -H. In some implementations, R 2 It is -CH3, and R 3 For -CH3. In some implementations, R 2 It is -H or -CH3, and R 3 For -H. In some implementations, R 2 It is -H, and R 3 For -H. In some implementations, R 2 For -CH3 and R 3 It is -H.

[0447] In other embodiments of this aspect, X is NR 3’ And Y is CR 4 In which X is NR 3’ And Y is CR 4 In some implementation schemes, R 3’It is -H, C1-C3 alkyl, -C3-C6 cycloalkyl, or -CN, and R 4 It is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms.

[0448] In some implementation schemes, R 3 ' is -H, C1-C3 alkyl, or C3-cycloalkyl. In some embodiments, R 3 'is -H, C1-C3 alkyl, or -CN. In some embodiments, R 3 'is -H, C3-cycloalkyl, or -CN.' In some embodiments, R 3 'is C1-C3 alkyl, C3-cycloalkyl, or -CN.' In some embodiments, R 3 ' is -H or C1-C3 alkyl. In some embodiments, R 3’ It is -H or -CH3. In some implementations, R 3 'is -H or C3-cycloalkyl.' In some embodiments, R 3 'For -H or -CN.' In some implementations, R 3 'It is a C1-C3 alkyl or C3-cycloalkyl.' In some embodiments, R 3 'It is a C1-C3 alkyl group or -CN.' In some embodiments, R 3 'is C3-cycloalkyl or -CN.' In some embodiments, R 3 'For -H.' In some implementations, R 3 'It is a C1-C3 alkyl group.' In some embodiments, R 3 'is -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2. In some embodiments, R 3’ For -CH3. In some implementations, R 3 'It is a C3-cycloalkyl group.' In some embodiments, R 3 'For -CN.

[0449] In some implementation schemes, R 4 It is an -H or C1-C3 alkyl group, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 4 It is -H or halogen. In some implementations, R 4 It is a C1-C3 alkyl or halogen, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 4 For -H. In some implementations, R 4It is a C1-C3 alkyl group, wherein the C1-C3 alkyl group is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 4 The derivative is -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2, wherein the -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2 is optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms. In some embodiments, R 4 For CH3. In some implementations, R 4 It is a halogen. In some implementations, R 4 It is -F, -Cl, or -Br. In some other embodiments, R 4 For -F. In some implementations, R 4 It can be -H, -F, or -CH3. In some implementations, R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen. In some embodiments, R 4 It can be -H, -CH3, -CD3, -CHF2, or -CH2CH3. In some implementations, R 4 It can be -H, -CH3, -CD3, -CHF2, or a halogen. In some embodiments, R 4 It can be -H, -CH3, -CD3, -CH2CH3, or a halogen. In some embodiments, R 4 It can be -H, -CH3, -CHF2, -CH2CH3, or a halogen. In some embodiments, R 4 It can be -H, -CD3, -CHF2, -CH2CH3, or a halogen. In some embodiments, R 4 It can be -CH3, -CD3, -CHF2, -CH2CH3, or a halogen. In some embodiments, R 4 It is -H or halogen. In some implementations, R 4 It is -CH3 or -CH2CH3. In some implementations, R 4 It can be -CH3, -CD3, or -CHF2.

[0450] In some implementation schemes, R 3 'is -H or -CH3, and R 4 It can be -H, -F, or -CH3. In some implementations, R 3 ' is -H, and R 4 It can be -H, -F, or -CH3. In some implementations, R 3 'is -CH3, and R 4 It can be -H, -F, or -CH3. In some implementations, R 3’It is -H or -CH3, and R 4 For -H. In some implementations, R 3’ It is -H or -CH3, and R 4 For -F. In some implementations, R 3 'is -H or -CH3, and R 4 For -CH3. In some implementations, R 3’ It is -H, and R 4 For -H. In some implementations, R 3 ' is -H, and R 4 For -F. In some implementations, R 3 ' is -H, and R 4 For -CH3. In some implementations, R 3 'is -CH3, and R 4 For -H. In some implementations, R 3 'is -CH3, and R 4 For -F. In some other implementations, R 3’ It is -CH3, and R 4 It is -CH3.

[0451] In some implementation schemes, R 5 For C6-C 14 aryl or 5 to 10-membered heteroaryl, wherein the C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution. In some embodiments, R 5 For C6-C 14 Aryl, wherein the C6-C 14 Aryl groups are selectively coated with 1-5 R groups. 9 Group substitution. In some embodiments, R 5 The phenyl group is a phenyl group, wherein the phenyl group is optionally surrounded by 1-5 R groups. 9 Group substitution. In some embodiments, R 5 It is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution. In some embodiments, R 5 It is a group of 5 to 10 heteroaryl groups composed of the following:

[0452] in Indicates a single or double bond, and wherein C6-C 14The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution. In some embodiments, R 5 It is a group of 5 to 10 heteroaryl groups composed of the following: in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution. In some embodiments, R 5 It is a group of 5 to 10 heteroaryl groups composed of the following:

[0453] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution. In some embodiments, R 5 It is a group of 5 to 10 heteroaryl groups composed of the following: The 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution. In some embodiments, R 5 It is a group of 5 to 10 heteroaryl groups composed of the following: The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution.

[0454] In some implementation schemes, R 5 It is a group of 5 to 10 heteroaryl groups composed of the following:

[0455] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution. In some embodiments, R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0456]

[0457] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution. In some embodiments, R 5It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution.

[0458] In some implementation schemes, R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4 to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0459] In some implementation schemes, R 6 -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’C1-C6 alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0460] In some implementation schemes, R 6 It is a C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4 to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, R 6 It is a C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, the C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkylene-NR moieties are substituted with alkylene-NR. 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C6 alkylene-OH or C1-C6 alkylene-CN. In some embodiments, R 6 It is a C1-C6 alkyl, C3-C6 cycloalkyl, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4- to 8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ In some implementations, R 6 It is a C1-C6 alkyl, C3-C6 cycloalkyl, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ In some implementations, R 6 C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C-C6 alkylene-OH or C1-C6 alkylene-CN. In some embodiments, R 6 C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR7’ R 8’ C1-C2 alkylene-(4-to-8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(4-to-8-membered heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C3-C7 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ In some implementations, R 6 C1-C6 alkylene-NR 7 R 8 C1-C6 alkylene-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ In other implementations, R 6 It is a C1-C6 alkylene-OH or a C1-C6 alkylene-CN. In some embodiments, R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ In some implementations, R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ , where R 6 Each pair of R 7’ and R 8’Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some other embodiments, R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ , where R 6 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, R 6 It is a C1-C3 alkyl group. In some embodiments, R 6 It is -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2. In some other embodiments, R 6 For -CH2CH3. In some implementations, R 6 C1-C3 alkylene-NR 7’ R 8’ In some implementations, each R 6 Independently, it is either an optionally substituted -C1-C2 alkylene-N-morpholino or an optionally substituted -C1-C2 alkylene-N-piperazino. In some embodiments, each R 6 Independently as an optional replacement Optional replacement Optional replacement Optional replacement Optional replacement Or optional replacement In some implementations, each R 6 Independently as an optional replacement Optional replacement Optional replacement Or optional replacement In some implementations, each R 6 Independently

[0461] In some implementations, each R 6 Independently In some other implementations, each R 6 Independently In other implementation schemes, each R 6 Independently

[0462] In some implementations, each R 7 Independently, it is -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl. In some embodiments, each R 7 Independently, it is -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl. In some embodiments, each R 7 Independently for -H. In some implementations, each R 7 Independently, each R is a C1-C3 alkyl group. In some embodiments, each R 7 Independently -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2. In some embodiments, each R 7 Independently, it is a C3-C6 cycloalkyl group. In some embodiments, R 7 It is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 7 Independently, it is a C2-C3 haloalkyl group. In some embodiments, each R... 7 Each is independently a C2-C3 haloalkyl group, wherein each halogen atom of each C2-C3 haloalkyl group is independently -F, -Cl, or -Br. In some embodiments, each R 7 Independently C2-C3 alkylene-CN. In some embodiments, each R 7 Independently, it can be -CH2CH2CN, -CH(CN)CH3, -CH2CH2CH2CN, -CH2CH(CN)CH3, -CH(CN)CH2CH3, or -CH(CH2CN)CH3. In some embodiments, each R 7 Independently, it is a C2-C3 heteroalkyl group. In some embodiments, each R 7Independently, it can be -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, -CH2CH(OH)CH3, or -CH(OH)CH2CH3, -CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH(OCH3)CH3, -CH(CH2OH)CH3, -CH2CH2NH2, -CH(NH2)CH3, -CH2CH2CH2NH2, -CH2CH(NH2)CH3, or -CH(NH2)CH2 CH3, -CH2NHCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH(NHCH3)CH3, -CH(CH2NH2CH3, -CH2CH2SH, -CH(SH)CH3, -CH2CH 2CH2SH, -CH2CH(SH)CH3 or -CH(SH)CH2CH3, -CH2SCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH(SCH3)CH3 or -CH(CH2SH)CH3.

[0463] In some implementations, each R 8 Independently, it is -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl. In some embodiments, each R 8 Independently, it is -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl. In some embodiments, each R 8 Independently for -H. In some implementations, each R 8 Independently, each R is a C1-C3 alkyl group. In some embodiments, each R 8 Independently -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2. In some embodiments, each R 8 Independently, it is a C3-C6 cycloalkyl group. In some embodiments, R 8 It is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 8 Independently, it is a C2-C3 haloalkyl group. In some embodiments, each R... 8 Each is independently a C2-C3 haloalkyl group, wherein each halogen atom of each C2-C3 haloalkyl group is independently -F, -Cl, or -Br. In some embodiments, each R 8 Independently C2-C3 alkylene-CN. In some embodiments, each R 8Independently, it can be -CH2CH2CN, -CH(CN)CH3, -CH2CH2CH2CN, -CH2CH(CN)CH3, -CH(CN)CH2CH3, or -CH(CH2CN)CH3. In some embodiments, each R 8 Independently, it is a C2-C3 heteroalkyl group. In some embodiments, each R 8 Independently, it can be -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, -CH2CH(OH)CH3, or -CH(OH)CH2CH3, -CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH(OCH3)CH3, -CH(CH2OH)CH3, -CH2CH2NH2, -CH(NH2)CH3, -CH2CH2CH2NH2, -CH2CH(NH2)CH3, or -CH(NH2)CH2 CH3, -CH2NHCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH(NHCH3)CH3, -CH(CH2NH2CH3, -CH2CH2SH, -CH(SH)CH3, -CH2CH 2CH2SH, -CH2CH(SH)CH3 or -CH(SH)CH2CH3, -CH2SCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH(SCH3)CH3 or -CH(CH2SH)CH3.

[0464] In some implementations, each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, R 1 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 3 to 8-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atom of any primary or secondary amine present in said heterocycle is optionally substituted with -H or C1-C3 alkyl groups. In some embodiments, each pair of R 7’ and R 8’Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl. In some embodiments, R 1 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atoms of any primary or secondary amines present in the heterocycles are optionally substituted with -H or C1-C3 alkyl groups.

[0465] In some implementations, each R 9 Independently, it is halogen, -OR 10 -NR 7 R 8 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl groups or S(O) n C3-C6 cycloalkyl, where n is an integer from 0 to 2. In some embodiments, each R 9 Independently, it is halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl, or -CN. In some embodiments, each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN. In some implementations, each R 9 Independently -F, -OR 10 Or -CH3. In some implementations, each R 9 Independent of -F or -OR 10 In some implementations, each R 9 It can be -F, -OH, -OCH3, or -OCD3 independently.

[0466] In some implementations, each R 10 Independently, it is -H, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group, a C1-C3 alkoxy group, and / or 1-6 deuterium atoms. In some embodiments, each R 10Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3, or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with a hydroxyl group and / or a C1-C3 alkoxy group and / or 1-6 deuterium atoms. In some embodiments, each R 10 Independently -H, -CH3, -CD3, -CH2CH3, or cyclopropyl, wherein the -CH3 or -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3. In some embodiments, each R 10 Independently -H, -CH3, -CD3, or -CH2CH3, wherein the -CH3 or -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3. In some embodiments, each R 10 Independently -H, -CH3, -CD3, -CF2H, or -CF3. In some implementations, each R 10 It can be -H or -CH3 independently.

[0467] In some embodiments, the compound of formula (I) is a compound of formula (IA), or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances:

[0468]

[0469] In some embodiments, the compound of formula (I) or formula (IA) is a compound of formula (IAi) or (IA-ii):

[0470]

[0471]

[0472] in

[0473] m is an integer, either 0 or 2;

[0474] Each R 1 Independently -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 The alkyl, alkylene, cycloalkylene, and heteroalkylene groups are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0475] R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3;

[0476] R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN;

[0477] R 3’ It can be -H, C1-C3 alkyl, C3-cycloalkyl or -CN;

[0478] R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen;

[0479] R 5 For C6-C 14 Aryl or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is selected from the group consisting of:

[0480]

[0481]

[0482] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0483] Each R 7 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0484] Each R 8Independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0485] Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0486] Each R 9 Independent of halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and

[0487] Each R 10 Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy and / or 1-6 deuterium atoms.

[0488] In some implementations, each R 1 Independently -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH; and wherein R 1 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atoms of any primary or secondary amines present in the heterocycles are optionally substituted with H or C1-C3 alkyl groups.

[0489] In some implementation schemes, R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution.

[0490] In some implementation schemes, R 2 For -CH3, CD3, or -CH2CH3; R 3-H, -F, -CH3, or -CN; R 3’ It is -H or -CH3; and R 4 It can be -H, -F, or -CH3.

[0491] In some implementations, each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN, and each R 10 Independently -H, -CH3, -CD3 or -CH2CH3, wherein the -CH3 or the -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3.

[0492] In some embodiments, the compound of formula (I) is a compound of formula (IAi) or formula (IA-ii), where m is an integer 0 or 1; R 1 -F, C1-C3 alkylene-NR 7’ R 8’ Or C1-C3 alkylene-OH; R 2 For -CH3, CD3, or -CH2CH3; R 3 -H, -F, -CH3, or -CN; R 3’ -H or -CH3; R 4 -H, -F, or -CH3; R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of:

[0493] in Indicates a single or double bond, and wherein the phenyl or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution; per pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atom of any primary or secondary amine present in said heterocycle is optionally substituted with H or C1-C3 alkyl; each R 9 Independently -F, -Cl, -OR 10 -CH3 or -CN, and each R 10 Independently -H, -CH3, -CD3 or -CH2CH3, wherein the -CH3 or the -CH2CH3 is optionally substituted with a hydroxyl group and / or -OCH3.

[0494] In some embodiments, the compound of formula (I) is a compound of formula (IAi) or formula (IA-ii), where m is an integer 0 or 1; R1 -F; R 2 -CH3; R 3 -H or -CH3; R 3’ -H or -CH3; R 4 -CH3; R 5 It is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: The 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution; each R 9 Independent of -F or -OR 10 And each R 10 It can be -H or -CH3 independently.

[0495] In some embodiments, the compound of formula (I) is a compound of formula (IB), or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances:

[0496]

[0497] In some embodiments, the compound of formula (I) or formula (IB) is a compound of formula (IBi) or (IB-ii):

[0498]

[0499] in

[0500] R 2 It can be -H, -CH3, CD3, -CHF2, or -CH2CH3;

[0501] R 3 It can be -H, C1-C3 alkyl, C3-cycloalkyl, halogen, or -CN;

[0502] R 3’ It can be -H, C1-C3 alkyl, C3-cycloalkyl or -CN;

[0503] R 4 It can be -H, -CH3, -CD3, -CHF2, -CH2CH3, or a halogen;

[0504] R 5 For C6-C 14 Aryl or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is selected from the group consisting of:

[0505]

[0506]

[0507] in Indicates a single or double bond, and wherein C6-C 14 The aryl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-5 R groups. 9 Group substitution;

[0508] R 6 It is a C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 alkylene-NR 7 R 8 C1-C3 alkylene-NR 7’ R 8’ C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 Or C1-C2 alkylene-(C4-C6 heterocyclic alkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 6 The alkyl, alkylene, cycloalkyl, cycloalkylene, and heteroalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and each heterocyclic nitrogen atom, if present, is independently and optionally substituted with a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl.

[0509] Each R 7 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0510] Each R 8 It can be independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN, or C2-C3 heteroalkyl;

[0511] Each pair of R 7’ and R 8’Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0512] Each R 9 Independent of halogen, -OR 10 C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and

[0513] Each R 10 Independently, it is -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy.

[0514] In some implementation schemes, R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ ; and R 6 Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein the heterocycles optionally contain 1 to 2 additional heteroatoms selected from the group consisting of N, O and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl.

[0515] In some implementation schemes, R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution.

[0516] In some implementations, each R 9 Independently -F, -OR 10 -CH3, and each R 10 It can be -H, -CH3, -CD3, -CF2H or -CF3 independently.

[0517] In some implementation schemes, R 2 -H or -CH3; R 3 -H;R 3’ It is -H; and R 4It can be H or -CH3.

[0518] In some embodiments, the compound of formula (I) is a compound of formula (IBi) or formula (IB-ii), wherein R 2 -H or -CH3; R 3 -H;R 3 'for -H;R 4 -H or -CH3; R 5 It is a phenyl or a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from: The phenyl group or the 5- to 10-membered heteroaryl group is optionally surrounded by 1-3 R groups. 9 Group substitution; R 6 It is a C1-C3 alkyl or C1-C3 alkylene-NR 7’ R 8’ ; Each pair of R 7’ and R 8’ Together with the nitrogen atoms to which they are attached, they independently form 4 to 6-membered heterocycles, wherein said heterocycles optionally contain an additional 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocycle nitrogen atom, if present, is independently and optionally substituted by a C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl; each R 9 Independently -F, -OR 10 -CH3, and each R 10 It can be -H, -CH3, -CD3, -CF2H or -CF3 independently.

[0519] In some embodiments, a compound selected from the compounds in Table 1 is provided, or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances.

[0520] Table 1

[0521]

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538] Although some compounds described in Table 1 exist as specific stereoisomers and / or in non-stereochemical forms, it should be understood that this document describes any or all non-stereochemical forms and any or all stereochemical forms of any compound in Table 1, including any enantiomers or diastereomers, as well as any tautomers or other forms. In some embodiments, the compounds described herein are selected from compounds 1-147.

[0539] This disclosure also includes all salts of the compounds mentioned herein, such as pharmaceutically acceptable salts. This disclosure also includes any or all stereochemical forms of the described compounds, including any enantiomers or diastereomers, and any tautomers or other forms such as N-oxides, solvates, hydrates, or isotopomers. This disclosure also includes eutectics of the compounds described herein. Unless the stereochemistry is explicitly indicated in the chemical structure or name, that structure or name is intended to include all possible stereoisomers of the depicted compound. Additionally, where a particular stereochemical form is depicted, it should be understood that the invention also includes other stereochemical forms. The invention also includes all forms of the compounds, such as crystalline or amorphous forms. Compositions containing the compounds of the invention are also contemplated, such as compositions of substantially pure compounds (including their specific stereochemical forms). Compositions containing mixtures of the compounds of the invention in any ratio are also included in the invention, including mixtures of two or more stereochemical forms of the compounds of the invention in any ratio, thereby including racemic, non-racemic, enantiomer-rich, and proportional mixtures of the compounds.

[0540] In the description herein, it should be understood that each description, variation, implementation, or aspect of a part can be combined with each description, variation, implementation, or aspect of other parts as if each combination were explicitly listed separately. For example, the R provided herein regarding equation (I) 0 Each description, variation, implementation, or aspect can be related to X, Y, m, R 1 R 2 R 3 R 3’ R 4 R 5 R 6 R 7 R 7’ R 8 R 8’ R 9 and / or R 10 Each description, variation, embodiment, or aspect combination thereof is described as if each combination were explicitly listed separately. It should also be understood that all descriptions, variations, embodiments, or aspects of formula (I), where applicable, are equally applicable to and described in the same way as other chemical formulas detailed herein, as if each description, variation, embodiment, or aspect were listed separately for each chemical formula. For example, all descriptions, variations, embodiments, or aspects of formula (I), where applicable, are equally applicable to any one of formulas (IA), (IAi), (IB), (IBi), and (IB-ii) detailed herein, and are described in the same way as if each description, variation, embodiment, or aspect were listed separately for each chemical formula.

[0541] III. General Synthesis Methods

[0542] The compounds disclosed herein can be prepared by a number of methods, as generally described below and more specifically described in the examples below (such as the methods provided in the examples below). In the following description of methods, when used in the depicted chemical formulas, the symbols should be understood to represent those groups described above that are relevant to the chemical formulas herein.

[0543] The intermediates described in the following preparations may contain a variety of nitrogen, hydroxyl, and acid protecting groups, such as esters. The variable protecting groups may be the same or different each time they appear, depending on the specific reaction conditions and the specific transformation to be performed. Protecting and deprotecting conditions are well known to those skilled in the art and are described in the literature. See, for example, Greene and Wuts, Protective Groups in Organic Synthesis (edited by T. Greene and P. Wuts, 2nd ed., 1991).

[0544] For clarity, certain stereochemical centers are not specified and certain substituents have been eliminated in the following scheme, and it is not intended to limit the teaching of the scheme in any way. Furthermore, individual isomers, enantiomers, and diastereomers can be separated or decomposed by those skilled in the art at any convenient point in the synthesis of the compounds of the present invention by methods such as selective crystallization or chiral chromatography (see, for example, J. Jacques et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981; and E.L. Leel and S.H. Wilen, "Stereochemistry of Organic Compounds", Wiley-Interscience, 1994).

[0545] The compounds of the present invention, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures thereof, can be prepared by a variety of procedures known in the art, some of which are illustrated in the examples below. The specific synthetic steps of each described route can be combined in different ways to prepare the compounds of this disclosure or their salts. The products of each step can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, grinding, and crystallization. Reagents and raw materials are readily available to those skilled in the art. Other reagents and raw materials can be prepared by standard organic and heterocyclic chemistry techniques similar to those used in the synthesis of known structurally similar compounds, as well as by the procedures described in the examples below (including any novel procedures).

[0546] The compounds of formula (I) can be prepared according to schemes A, B, C, D, E, F, G, H, I, and J, wherein R 1 R 2 R 3 R 3 '、R 4 R 5 R 6 , and m are as defined for formula (I) or any applicable variant thereof as detailed herein. More specifically, compounds of formulas (IA), (IAi), and (IA-ii) can be prepared as described in schemes A, B, E, F, I, and J; compounds of formulas (IB), (IBi), and (IB-ii) can be prepared as described in schemes A, B, C, D, E, F, G, H, I, and J.

[0547] Option A - Part I.

[0548]

[0549] Option A - Part II.

[0550]

[0551] Plan A - Part III.

[0552]

[0553] Compounds of (IAi) can be prepared according to the general synthetic schemes shown in parts I-III of scheme A. In part I of scheme A, 6-azaindole compounds of general formula Aia (where LG) 1 It is a leaving group (such as chlorine or bromine), with a protected group P at the nitrogen of the imidazole group. 1 (For example, protected by a Boc- group or a SEM- group) to obtain compounds of the general formula Aib. A suitable leaving group LG is then added. 2 (Such as iodine) is added to the protected compound of the general formula Aib, to form R. 5 Prepare for partial installation. Further react the resulting compound of general formula Aic, introducing a substituent R onto the 6-azaindole core as needed. 2 'and R 3 To produce an intermediate compound of the general formula Aih. As shown in scheme A, R 2 'Having the same R as described in this article 2 The same definition, unless R 2 For hydrogen, in this case, R 2 ' is the protecting group P 1 Similarly, substituent R 3 "Having the same as R" 3 The same definition, except for R 3 "Excluding hydrogen." LG 3 and LG 4 It is a leaving group, such as chlorine, bromine or iodine.

[0554] In part II of scheme A, R 5 The addition of aryl or heteroaryl moieties to compounds of the general formula Aih is LG 2 The occupied position yields other intermediate compounds of the general formula Ail. R 5 Partial installation can be achieved, for example, via the two routes shown above. In the first route, a compound of the general formula Aih reacts with a suitable boric acid derivative containing the desired R. 5 Group Aik, where R A and R BIndependently selected from halogens, OH and O- (C1-C6 alkyl), or R A and R B Together with the attached boron atoms, they form 5-10 membered heterocycles to obtain intermediate compounds of formula Ail. In the second route, compounds of formula Aih react directly with boric acid or its derivatives, wherein R... c A suitable leaving group (such as an O-C1-C3 alkyl group, or another boronic acid or its derivative, i.e., in a diboronic compound) yields a 6-azaindolyl-borate compound of formula Aii. The resulting borate compound is further reacted with an R-containing group... 5 The substrate (Aij) reacts to give a compound of formula Ail.

[0555] In Part III of Scheme A, the compound of formula Ail is reacted with a suitable cyclopropaneformamide of formula Aim to give the compound of formula IAi.

[0556] Option B - Part I.

[0557]

[0558] Plan B - Part II.

[0559]

[0560] Plan B - Part III.

[0561]

[0562] Similar to Scheme A, Scheme B describes the preparation of compounds of formula (IA-ii) having a 5-azaindole core. Compounds of formula (IA-ii) can be prepared according to the general synthetic schemes shown in parts I-III of Scheme B. In part I of Scheme B, 5-azaindole compounds of general formula A-ii-a (where LG...) are... 1 It is a leaving group (such as chlorine or bromine), with a protected group P at the nitrogen of the imidazole group. 1 (For example, protected by a Boc- group or a SEM- group) to obtain a compound of general formula A-ii-b. A suitable leaving group LG is then added. 2 (Such as iodine) is added to protected compounds of the general formula A-ii-b, to form R. 5 Preparations are made for partial installation. The resulting compound of general formula A-ii-c is further reacted, and a substituent R is introduced onto the 5-azaindole core as needed. 4 'and R 3 ', to produce an intermediate compound of general formula A-ii-h. As shown in scheme B, the substituent R 3 '" has the same characteristics as R 3The same definition, unless R 3 '" represents hydrogen, in which case R 3 '" is the protecting group P 1 Similarly, R 4 'Having the same R as described in this article 4 The same definition, except for R 4 Excluding hydrogen. LG 3 and LG 4 It is a leaving group, such as chlorine, bromine or iodine.

[0563] In part II of scheme B, R 5 The addition of aryl or heteroaryl moieties to compounds of the general formula A-ii-h is LG 2 The occupied position yields other intermediate compounds of the general formula A-ii-l. R 5 Partial installation can be achieved, for example, via the two routes shown above. In the first route, a compound of general formula A-ii-h reacts with a suitable boric acid derivative containing the desired R. 5 Group A-ii-k, where R A and R B Independently selected from the group consisting of halogens, OH, and O-(C1-C6 alkyl), or R A and R B Together with the attached boron atoms, they form 5-10 membered heterocycles to yield intermediate compounds of formula A-ii-l. In the second route, compounds of formula A-ii-h react directly with boric acid or its derivatives, wherein R... c A suitable leaving group (such as an O-C1-C3 alkyl group, or another boronic acid or its derivative, i.e., in a diboronic compound) yields a 5-azaindolyl-borate compound of formula A-ii-i. The resulting borate compound is further reacted with an R-containing group... 5 The substrate (A-ii-j) reacts to give a compound of formula A-ii-l.

[0564] In part III of scheme B, a compound of formula A-ii-l is reacted with a suitable cyclopropaneformamide of formula A-ii-m to give a compound of formula IA-ii.

[0565] Compounds of formula (IB) can also be prepared according to the general synthetic schemes shown in schemes C and D. In scheme C, a 6-azaindolyl compound of formula Ail obtained from scheme A (parts I and II) is reacted with a suitable urea compound of formula Bim to give a compound of formula IBi. In scheme D, a 5-azaindolyl compound of formula A-ii-l obtained from scheme B (parts I and II) is reacted with a suitable urea compound of formula B-ii-m to give a compound of formula IB-ii.

[0566] Option C.

[0567]

[0568] Option D.

[0569]

[0570] Alternatively, the addition of the cyclopropylformamide group or urea moiety as described in Scheme A (part III), Scheme B (part III), Scheme C and Scheme D can be replaced by the methods described in Scheme E, Scheme F, Scheme G and Scheme H, respectively.

[0571] Option E.

[0572]

[0573] In scheme E, an intermediate compound of general formula Ail is amination (e.g., with diphenylmethyleneimine) to obtain a compound of general formula Ain. The resulting compound of general formula Ain is then reacted with a cyclopropane carboxylic acid or its derivative Aio (where LG... 5 It can be -OH, Cl-, -O-C1-C6 alkyl, etc.) reacted to give the desired compound of formula (IAi). Similarly, in scheme F, the intermediate compound of general formula A-ii-l is amination (e.g., with diphenylmethyleneimine) to give a compound of general formula A-ii-n. The resulting compound of general formula A-ii-n is then reacted with cyclopropane carboxylic acid or its derivative A-ii-o (where LG) 5 It can be a reaction of -OH, Cl-, -O-C1-C6 alkyl, etc., to obtain the desired compound of formula (IA-ii).

[0574] Option F.

[0575]

[0576] Compounds of general formula (IB) can also be prepared from compounds of formulas Ain and A-ii-n as described in schemes G and H. In scheme G, compounds of general formula Ain are prepared by reacting with carboxylic acid derivatives (e.g., phenyl carbonyl chlorides and R-containing compounds). 6 The free amine Bio reacts in a series of steps to give urea compounds of the general formula IBi. Similarly, in scheme H, compounds of the general formula A-ii-n react with carboxylic acid derivatives and R-containing compounds. 6 The free amine B-ii-o reacts in a series of steps to give the desired urea compound of the general formula IB-ii.

[0577] Option G.

[0578]

[0579] Option H.

[0580]

[0581] Schemes I and J below describe alternative methods for preparing 5-azaindole and 6-azaindole intermediates in the synthesis of compounds of general formula (I). In Scheme I, the 3-aminopyridine compound of formula Aip (wherein LG) 6 It is a leaving group (e.g., iodine) and an R-containing group of formula Aiq. 3 and R 5 The reaction of an acetylene compound provides an intermediate compound of formula Air. In scheme J, a 4-aminopyridine compound of formula A-ii-p reacts with an R-containing compound of formula A-ii-q. 4 and R 5 The reaction of acetylene compounds provides an intermediate compound of formula A-ii-r.

[0582] Option I.

[0583]

[0584] Option J.

[0585]

[0586] Prior to coupling, the intermediate compounds of formula Air and formula A-ii-r can be further reacted, for example, by adding or removing any protecting groups or introducing substituents R. 2 or R 3 This yields the final cyclopropylformamide compounds of formula (IAi) and (IA-ii) or urea compounds of formula (IBi) and (IB-ii) as shown in schemes A to H.

[0587] IV. Pharmaceutical compositions and formulations

[0588] Any of the compounds described herein can be formulated into pharmaceutically acceptable compositions.

[0589] Pharmaceutical compositions of any compounds detailed herein are included in this disclosure. Therefore, this disclosure includes pharmaceutical compositions comprising compounds as detailed herein, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures of any of the foregoing substances, and pharmaceutically acceptable carriers or excipients. In one aspect, pharmaceutically acceptable salts are acid addition salts, such as salts formed with inorganic or organic acids. Pharmaceutical compositions may be in forms suitable for oral, sublingual, parenteral, intranasal, topical, or rectal administration, or in forms suitable for inhalation.

[0590] The compounds detailed herein may be in a purified form, and compositions comprising the purified form of the compounds are described herein. Compositions comprising the compounds detailed herein or their pharmaceutically acceptable salts, solvates, hydrates, or cocrystals, or mixtures of any of the foregoing substances, are provided, such as compositions of substantially pure compounds. In some embodiments, compositions comprising the compounds detailed herein or their pharmaceutically acceptable salts, solvates, hydrates, or cocrystals, or mixtures of any of the foregoing substances, are in substantially pure form. In one variation, “substantially pure” means a composition containing no more than 35% impurities, where impurities represent compounds other than the compounds constituting the majority of the composition or their salts. For example, a composition of substantially pure compounds selected from the compounds in Table 1 means a composition containing no more than 35% impurities, where impurities represent compounds other than those in Table 1. In one variation, compositions comprising substantially pure compounds or their pharmaceutically acceptable salts, solvates, hydrates, or cocrystals, or mixtures of any of the foregoing substances, are provided, wherein the compositions contain no more than 25% impurities. In another variation, a composition is provided of a substantially pure compound or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the composition contains no more than 20% impurities. In another variation, a composition is provided of a substantially pure compound or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the composition contains no more than 10% impurities. In another variation, a composition is provided of a substantially pure compound or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the composition contains no more than 5% impurities. In another variation, a composition is provided of a substantially pure compound or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the composition contains no more than 3% impurities. In yet another variation, a composition is provided of a substantially pure compound or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the composition contains no more than 1% impurities. In another variation, a composition is provided that is substantially pure of a compound or a pharmaceutically acceptable salt, solvate, hydrate, or eutectic thereof, or a mixture of any of the foregoing substances, wherein the composition contains no more than 0.5% impurities. In other variations, a composition of substantially pure compounds means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% impurities, which may be compounds in different stereochemical forms. For example, but not limited to, a composition of substantially pure (S) compounds means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of a (R) form of the compound.

[0591] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual. In another variation, compositions comprising the compounds in substantially pure form are provided. In yet another variation, this disclosure includes pharmaceutical compositions comprising the compounds detailed herein and a pharmaceutically acceptable carrier. In yet another variation, methods of administering the compounds are provided. Purified forms, pharmaceutical compositions, and methods of administering the compounds are suitable for any of the compounds or forms thereof detailed herein. In some embodiments, the compounds and compositions provided herein are sterile. Sterilization methods known in the art are suitable for any of the compounds or forms thereof and compositions thereof detailed herein.

[0592] The compounds detailed herein, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures thereof, may be formulated for any available route of delivery, including oral, mucosal (e.g., nasal, sublingual, vaginal, oral, or rectal), parenteral (e.g., intramuscular, subcutaneous, or intravenous), topical, or percutaneous delivery. The compounds, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures thereof, may be formulated with a suitable carrier to provide a delivery form, including but not limited to tablets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), flat capsules, lozenges, sugar lozenges, gums, dispersants, suppositories, ointments, mud dressings, pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil emulsions), solutions, and elixirs.

[0593] The compounds detailed herein, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures thereof, may be used to prepare formulations, such as pharmaceutical formulations, by combining one or more of the compounds, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures thereof, with a pharmaceutically acceptable carrier. The carrier may take various forms depending on the systemic therapeutic form (e.g., transdermal patches and oral tablets). Additionally, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, modifiers, and salts, buffers, coating agents, or antioxidants for adjusting osmotic pressure. Formulations containing the compounds may also contain other substances with valuable therapeutic properties. Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 20th edition (2000), which is incorporated herein by reference.

[0594] The compounds detailed herein, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures of any of the foregoing, may be administered to an individual in the form of generally acceptable oral compositions, such as tablets, coated tablets, and gel capsules, emulsions, or suspensions in hard or soft shells. Examples of carriers that can be used to prepare such compositions are lactose, corn starch or derivatives thereof, talc, stearates or salts thereof, etc. Acceptable carriers for soft-shell gel capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, etc. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts, buffers, coating agents, or antioxidants for adjusting osmotic pressure.

[0595] Any compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or any mixture thereof, may be formulated into tablets of any of the aforementioned dosage forms. For example, a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or any mixture thereof, may be formulated into a 10 mg tablet.

[0596] Compositions comprising the compounds provided herein or their pharmaceutically acceptable salts, solvates, hydrates, or cocrystals, or mixtures of any of the foregoing substances, are also described. In one variation, the composition comprises the compound or its pharmaceutically acceptable salts, solvates, hydrates, or cocrystals, or mixtures of any of the foregoing substances, and a pharmaceutically acceptable carrier or excipient. In another variation, compositions comprising substantially pure compounds or their pharmaceutically acceptable salts, solvates, hydrates, or cocrystals, or mixtures of any of the foregoing substances, are provided. In some embodiments, the compositions are used as human or veterinary medicines. In some embodiments, the compositions are used in the methods described herein. In some embodiments, the compositions are used for the treatment of the diseases or conditions described herein.

[0597] Compositions formulated for co-administration of the compounds provided herein and one or more other pharmaceutical agents are also described. Co-administration can be performed simultaneously or sequentially in any order. The compounds provided herein can be formulated for co-administration with the one or more other pharmaceutical agents in the same dosage form (e.g., a single tablet or a single intravenous injection) or in separate dosage forms (e.g., two separate tablets, two separate intravenous injections, or one tablet and one intravenous injection). Furthermore, co-administration can be, for example, 1) simultaneous delivery via the same route of delivery (e.g., tablet or intravenous injection), 2) sequential delivery on the same day via the same or different routes of delivery, or 3) delivery on different days via the same or different routes of delivery.

[0598] V. Usage Instructions

[0599] The compounds and compositions detailed herein, such as compounds containing formula (I) provided herein or any variant thereof, or pharmaceutically acceptable salts, solvates, hydrates or cocrystals thereof, or mixtures of any of the foregoing substances, and pharmaceutical compositions comprising pharmaceutically acceptable carriers or excipients, may be used in the administration and treatment methods provided herein. The compounds and compositions may also be used in in vitro methods, such as in vitro methods of applying the compounds or compositions to cells for screening purposes and / or for quality control assays.

[0600] In one aspect, this document provides a method for inhibiting the enzymatic activity of Bcr-Abl tyrosine kinase, comprising contacting an effective amount of the compound or composition provided herein with Bcr-Abl tyrosine kinase. In some embodiments, this document provides a method for inhibiting Bcr-Abl tyrosine kinase in cells, comprising administering an effective amount of the disclosed compound or composition to the cells. In some embodiments, this document provides a method for inhibiting Bcr-Abl tyrosine kinase in an individual in need, comprising administering an effective amount of the compound or composition of the present invention to said individual. In some variations, the compounds provided herein selectively inhibit Bcr-Abl tyrosine kinase. Thus, in some embodiments, this document provides a method for selectively inhibiting Bcr-Abl tyrosine kinase compared to other tyrosine kinases, including but not limited to c-KIT, FGFR, PDGFR, SRC, CSFR1, or VEGFR.

[0601] The compounds and compositions described herein may be used in methods for treating diseases or conditions mediated by Bcr-Abl tyrosine kinase activity. In some embodiments, the compounds or compositions are administered according to the dosages described herein.

[0602] In some embodiments, this document provides a method for treating a disease or condition mediated by Bcr-Abl tyrosine kinase activity, comprising administering to an individual in need of treatment an effective amount of a compound of formula (I) or any variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances. In some embodiments, the disease or condition is cancer mediated by Bcr-Abl tyrosine kinase activity. In some embodiments, the disease or condition is chronic myeloid leukemia (CML), acute myeloid leukemia (AML), or acute lymphoblastic leukemia (ALL). In some embodiments, the disease or condition is cancer, such as leukemia. In some variations, the cancer is chronic myeloid leukemia (CML), Philadelphia positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia.

[0603] In some embodiments, the leukemia is chronic myeloid leukemia (CML). CML may be characterized by the stage of disease progression, such as that determined by the blast cell. In further embodiments, CML is chronic phase CML, accelerated phase CML, or blast crisis CML. In some embodiments, CML is refractory CML.

[0604] In some embodiments, the disease or condition mediated by Bcr-Abl tyrosine kinase activity is refractory or tolerable to first-line, second-line, and / or third-line treatment. In some embodiments, the symptom mediated by Bcr-Abl tyrosine kinase activity is refractory or tolerable to treatment with one or more Bcr-Abl tyrosine kinase inhibitors selected from the group consisting of imatinib, nilotinib, dasatinib, bafetinib, bosutinib, radotinib, asciminib, and ponatinib. First-line treatment as described herein includes the use of imatinib; second-line and third-line treatments as described herein include the use of nilotinib, dasatinib, bafetinib, bosutinib, radotinib, asciminib, and / or ponatinib. Among the aforementioned variants, chronic myeloid leukemia is a refractory form of chronic myeloid leukemia.

[0605] Bcr-Abl tyrosine kinase-mediated disease or condition resistance subtypes may be associated with many Bcr-Abl-dependent or Bcr-Abl-independent resistance mechanisms. In some embodiments where Bcr-Abl tyrosine kinase activity-mediated disease or condition is refractory to treatment, the disease or condition is characterized as being associated with one or more Bcr-Abl-dependent resistance mechanisms. Bcr-Abl-dependent resistance mechanisms include, but are not limited to, one or more point mutations that produce amino acid substitutions at the following positions in Bcr-Abl tyrosine kinases: M244, L248, G250, G250, Q252, Q252, Y253, Y253, E255, E255, D276, F311, T315, F317, F317, M343, M351, E355, F359, F359, V379, F382, L387, H396, H396, S417, E459, or F486. In certain variants, refractory disease or symptoms mediated by Bcr-Abl tyrosine kinase are associated with one or more specific point mutations in the Bcr-Abl tyrosine kinase gene that produce specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I. In some embodiments, refractory disease or condition mediated by Bcr-Abl tyrosine kinase is associated with a mutation resulting in a T315I substitution. In a further embodiment, refractory disease or condition mediated by Bcr-Abl tyrosine kinase is associated with a T315I mutation at the start of treatment and an I315M mutation after panatinib. In other embodiments, refractory disease or condition mediated by Bcr-Abl tyrosine kinase is associated with one or more mutations (M244V, G250E, Q252H, Y253H / F, E255K / V) leading to amino acid substitution within the P-ring.

[0606] In some embodiments, a method of treating cancer in an individual in need is provided, comprising administering to the individual an effective amount of a compound of formula (I) as described herein, or any variant thereof. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the cancer is chronic myeloid leukemia (CML). In some embodiments, the leukemia is chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia is refractory. In some embodiments, the leukemia is chronic myeloid leukemia. In a further embodiment, chronic myeloid leukemia is refractory chronic myeloid leukemia. In other embodiments, chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia is refractory due to an associated T315I mutation. In some of the foregoing embodiments, chronic myeloid leukemia is refractory chronic myeloid leukemia associated with a T315I mutation.

[0607] In one aspect, this document provides a method for treating cancer in an individual in need, wherein modulation of Bcr-Abl tyrosine kinase activity inhibits or improves the pathology and / or symptoms of cancer, the method comprising administering to the individual a therapeutically effective amount of a compound or composition provided herein. In one embodiment, this document provides a method for treating cancer, wherein modulation of Bcr-Abl tyrosine kinase activity inhibits the pathology and / or symptoms of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of a compound or composition provided herein. In one embodiment, this document provides a method for treating cancer, wherein modulation of Bcr-Abl tyrosine kinase activity improves the pathology and / or symptoms of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of a compound or composition provided herein.

[0608] In another aspect, this article provides a method for cancer prevention, wherein modulation of Bcr-Abl tyrosine kinase activity prevents the pathology and / or symptoms of cancer in an individual, said method comprising administering to said individual a therapeutically effective amount of a compound or composition provided herein. In yet another aspect, this article provides a method for delaying the onset and / or development of cancer mediated by Bcr-Abl tyrosine kinase activity in individuals (such as humans) at risk of developing cancer. It is understood that, in the absence of cancer development in an individual, delaying development can encompass prevention.

[0609] In one aspect, this document provides a method for delaying the onset and / or development of cancer in an individual in need, comprising administering to said individual a therapeutically effective amount of a compound or composition provided herein. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the cancer is chronic myeloid leukemia. In some embodiments, the leukemia is chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia is refractory. In some embodiments, the leukemia is chronic myeloid leukemia. In a further embodiment, chronic myeloid leukemia is refractory chronic myeloid leukemia. In other embodiments, chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia is refractory due to an associated T315I mutation. In still other embodiments, chronic myeloid leukemia is refractory chronic myeloid leukemia associated with a T315I mutation. In one aspect, this document provides a method for delaying the onset and / or development of chronic myeloid leukemia in an individual in need, comprising administering to said individual a therapeutically effective amount of a compound or composition provided herein. In another aspect, this document provides a method for delaying the onset and / or development of refractory chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia in an individual in need, comprising administering to said individual a therapeutically effective amount of a compound or composition provided herein. In one aspect, this article provides a method for delaying the onset and / or development of refractory chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia associated with the T315I mutation in individuals in need, comprising administering to said individual a therapeutically effective amount of a compound or composition provided herein.

[0610] In one aspect, this document provides compounds of formula (I) or any variant thereof, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures of any of the foregoing substances, for use in therapy. In some embodiments, this document provides compounds of formula (I) or any variant thereof, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures of any of the foregoing substances, or pharmaceutical compositions comprising such compounds, for use in the treatment of cancer. In some embodiments, this document provides compounds of formula (I) or any variant thereof, or pharmaceutically acceptable salts, solvates, hydrates, or cocrystals thereof, or mixtures of any of the foregoing substances, or pharmaceutical compositions comprising such compounds, for use in the treatment of chronic myeloid leukemia (CML), Philadelphia positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, a compound of formula (I) or any variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition comprising such a compound, is provided for use in the treatment of chronic myeloid leukemia (CML). In some embodiments, a compound of formula (I) or any variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition comprising such a compound, is provided for use in the treatment of refractory chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, a compound of formula (I) or any variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate or cocrystal thereof, or a mixture of any of the foregoing substances, or a pharmaceutical composition comprising such a compound, is provided for use in the treatment of refractory chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia associated with the T315I mutation.

[0611] In another embodiment, this document provides a compound of formula (I) or any variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, for use in the manufacture of a pharmaceutical agent for treating cancer. In another embodiment, this document provides a compound of formula (I) or any variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, for use in the manufacture of a pharmaceutical agent for treating chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the pharmaceutical agent is used to treat chronic myeloid leukemia. In some embodiments, the pharmaceutical agent is used to treat refractory chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the pharmaceutical agent is used to treat refractory chronic myeloid leukemia. In other embodiments, the agent is used to treat refractory chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia associated with the T315I mutation. In some embodiments, the agent is used to treat refractory chronic myeloid leukemia associated with the T315I mutation.

[0612] In some embodiments, the individual is a mammal. In some embodiments, the individual is a primate, dog, cat, rabbit, or rodent. In some embodiments, the individual is a primate. In some embodiments, the individual is a human. In some embodiments, the human is any age at least about or about 18, 21, 30, 50, 60, 65, 70, 75, 80, or 85 years old. In some embodiments, the human is a child. In some embodiments, the human is less than or about 21, 18, 15, 10, 5, 4, 3, 2, or 1 year old.

[0613] In some embodiments, the method further includes administering one or more additional pharmaceutical agents. In some embodiments, the method further includes administering irradiation. In some embodiments, the method further includes administering one or more additional pharmaceutical agents, including antimicrotubule therapy (e.g., paclitaxel, vincristine), topoisomerase inhibitors (e.g., doxorubicin), alkylating agents (e.g., busulfan, cyclophosphamide), nucleotide synthesis inhibitors (hydroxyurea), DNA synthesis inhibitors (e.g., cytarabine), protein synthesis inhibitors (e.g., omacetaxine), developmental signaling pathway inhibitors (e.g., sonidegib, Hedgehog pathway), pro-apoptotic agents (e.g., venetoclax), Abl myristoyl-pocket binding inhibitors (e.g., acimenide), MEK1 / 2 inhibitors (e.g., trametinib, binimetinib), AKT inhibitors (e.g., ipatasertib), PI3K inhibitors (e.g., apelisib), and irradiation.

[0614] VI. Administration and Procedures

[0615] The dosage of the compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or any mixture thereof, administered to an individual (such as a human) may vary depending on the specific compound being treated, the method of administration, and the specific cancer (e.g., the type and stage of the cancer). In some embodiments, the amount of the compound, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or any mixture thereof, is a therapeutically effective amount.

[0616] The compounds provided herein, or their pharmaceutically acceptable salts, solvates, hydrates or cocrystals, or mixtures thereof, may be administered to an individual via various routes, including, for example, intravenous, intramuscular, subcutaneous, oral and transdermal administration.

[0617] In one respect, the effective amount of the compound can be a dose of about 0.01 to about 100 mg / kg. The effective amount or dose of the compounds disclosed herein can be determined by conventional methods, such as modeling, dose escalation, or clinical trials, taking into account conventional factors, such as the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and duration of the disease to be treated, the health status, symptoms, and weight of the subject. Exemplary doses range from about 0.7 mg to 7 g per day, or from about 7 mg to 350 mg per day, or from about 350 mg to 1.75 g per day, or from about 1.75 g to 7 g per day.

[0618] In one respect, any method provided herein may include administering a pharmaceutical composition to an individual containing an effective amount of the compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances, and a pharmaceutically acceptable excipient.

[0619] The compounds or compositions described herein may be administered to an individual for the required time or duration according to an effective dosing regimen, such as at least about one month, at least about two months, at least about three months, at least about six months, or at least about twelve months or longer, and in some variations, for the lifetime of the individual. In one variation, the compound is administered on a daily or intermittent schedule. The compound may be administered to an individual continuously for a period of time (e.g., at least once daily). The dosing frequency may also be less than once daily, for example, about once a week. The dosing frequency may be more than once daily, for example, twice or three times daily. The dosing frequency may also be intermittent, including "drug holidays" (e.g., once daily for seven days, followed by seven days without dosing, repeated for any 14-day period, such as about two months, about four months, about six months, or longer). Any dosing frequency may be achieved with any of the compounds described herein and any of the dosages described herein.

[0620] VII. Products and Reagent Kits

[0621] This disclosure further provides the inclusion in suitable packaging of the compounds described herein, or pharmaceutically acceptable salts, solvates, hydrates, or eutectics thereof, or mixtures of any of the foregoing, the compositions described herein, or one or more unit doses of the articles described herein. In some embodiments, the articles are used in any of the methods described herein. Suitable packaging is known in the art and includes, for example, vials, containers, ampoules, bottles, wide-mouth bottles, flexible packaging, etc. The articles may be further sterilized and / or sealed.

[0622] This disclosure also provides a kit for carrying out the methods of this disclosure, comprising one or more of the compounds described herein or a composition comprising the compounds described herein. The kit may employ any of the compounds disclosed herein. In one variation, the kit employs a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a mixture of any of the foregoing substances. The kit may be used for any one or more of the purposes described herein and may therefore contain instructions for treating any of the diseases described herein, such as for treating cancer, including chronic myeloid leukemia (CML), Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), acute myeloid leukemia (AML), or mixed phenotype acute leukemia. In some embodiments, the cancer is chronic myeloid leukemia. In some embodiments, the cancer is refractory chronic myeloid leukemia. In some of the foregoing embodiments, the cancer is refractory chronic myeloid leukemia associated with the T315I mutation.

[0623] The kit may optionally include a container containing one or more additional pharmaceutical reagents, and the kit may also include instructions for treating a subject with an effective amount of one or more additional pharmaceutical reagents, which are included on or in the packaging insert.

[0624] Kits typically include suitable packaging. A kit may include one or more containers containing any of the compounds described herein. Each component (if more than one component is present) may be packaged in a separate container, or, where cross-reactivity and shelf life permit, some components may be combined in one container.

[0625] The kit may be in unit dosage form, bulk packaging (e.g., multi-dose packaging), or subunit dosage. For example, a kit may be provided containing sufficient doses of the compounds disclosed herein and / or additional pharmaceutically active compounds applicable to the diseases detailed herein, to provide effective treatment to an individual over a prolonged period, such as one week, two weeks, three weeks, four weeks, six weeks, eight weeks, three months, four months, five months, seven months, eight months, nine months, or longer. The kit may also include multiple unit doses of the compound and instructions for use, and be packaged in quantities sufficient for storage and use in a pharmacy (e.g., hospital pharmacies and chemical pharmacies).

[0626] The kit may optionally include a set of instructions, typically written, but electronic storage media (e.g., disks or optical discs) containing instructions relating to the use of the components of the methods disclosed herein. The instructions included with the kit typically include information about the components and their administration to an individual.

[0627] Example

[0628] It should be understood that this disclosure is by way of example only and that those skilled in the art can make various changes to the combination and arrangement of parts without departing from the spirit and scope of this disclosure.

[0629] Synthesis Examples

[0630] The chemical reactions described in the examples can be readily applied to the preparation of many other compounds disclosed herein, and alternative methods for preparing the compounds of this disclosure are considered to be within the scope of this disclosure. For example, the synthesis of non-exemplary compounds according to this disclosure can be successfully carried out with modifications apparent to those skilled in the art, such as by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art besides those described, or by conventional modifications to reaction conditions, reagents, and starting materials. Alternatively, other reactions disclosed herein or known in the art will be considered suitable for the preparation of other compounds of this disclosure.

[0631] The abbreviations used in the examples include the following: ACN: acetonitrile; Brettphos: 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl; dppf: 1,1'-ferrocene di-bis(diphenylphosphine); DCM: dichloromethane; DIAD: diisopropyl azodicarboxylate; DIEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: dimethylformamide; DMSO: dimethyl sulfoxide; EDA: ethylenediamine; EtOAc: ethyl acetate; EtOH: ethanol or ethyl alcohol; F-TEDA-BF4: 1-chloromethyl-4-fluoro-1,4-diazoonium bicyclo[2.2.2]octanebis(tetrafluoroborate); 1 H NMR: Proton nuclear magnetic resonance; HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxyhexafluorophosphate, hexafluorophosphate azirbenztriazole tetramethylureonium; LCMS: Liquid chromatography-mass spectrometry; LDA: Lithium diisopropylamino; LiHMDS: Lithium hexamethyldisilazane; MeOH: Methanol or methyl alcohol; NBS: N-bromosuccinimide; NIS: N-iodosuccinimide; NNMP: N-methyl-2-pyrrolidone; OAc: Acetate; Py: Pyridine; TBAB: Tetra-n-butylammonium bromide; TBAF: Tetra-n-butylammonium fluoride; TEA: Triethylamine; TFA: Trifluoroacetic acid; THF: Tetrahydrofuran; and TLC: Thin-layer chromatography.

[0632] Example S1: Synthesis of N-(2-(2-hydroxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 1)

[0633]

[0634] Step 1: Synthesis of tert-butyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid (compound 1b)

[0635]

[0636] Cs₂CO₃ (compound 1a) (38.4 g, 117.99 mmol) and Boc₂O (12.8 g, 58.98 mmol) were added to a stirred solution of 5-chloro-1H-pyrrolo[2,3-c]pyridine (6.0 g, 39.34 mmol) in DCM (100.0 mL). The resulting mixture was stirred at room temperature for 16 hours. After the reaction was complete, the reaction mixture was diluted with H₂O and extracted with CH₂Cl₂. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (3 / 1 v / v) to give tert-butyl 5-chloropyrrolo[2,3-c]pyridine-1-carboxylic acid (compound 1b) (8.0 g, 80%) as a white solid. LCMS (ESI): [M+H] + =253.1.

[0637] Step 2: Synthesis of tert-butyl 5-chloro-2-iodopyrrolo[2,3-c]pyridine-1-carboxylic acid (compound 1c)

[0638]

[0639] At -78°C under N2, LDA (8.0 mL, 16.0 mmol) was added dropwise to a solution of 5-chloropyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (compound 1b) (2.0 g, 7.95 mmol) in THF (10.0 mL). The resulting mixture was stirred at -78°C under N2 for 1 hour. Then, a solution of iodine (3.0 g, 11.82 mmol) in THF (10.0 mL) was added dropwise to the mixture at -78°C. The mixture was stirred at -78°C under N2 for 4 hours. After the reaction was complete, the reactants were quenched with NH4Cl solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (5 / 1 v / v) to give tert-butyl 5-chloro-2-iodopyrrolo[2,3-c]pyridine-1-carboxylic acid (compound 1c) (1.0 g, 13%) as a white solid. LCMS (ESI): [M+H] + =379.0.

[0640] Step 3: Synthesis of 5-chloro-2-iodo-1H-pyrrolo[2,3-c]pyridine (compound 1d)

[0641]

[0642] TFA (3.0 mL) was added to a stirred solution of 5-chloro-2-iodopyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (compound 1c) (1.0 g, 2.61 mmol) in CH2Cl2 (5.0 mL). The resulting mixture was stirred at room temperature for 2 hours. After the reaction was complete, the resulting solution was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1 v / v) to give 5-chloro-2-iodo-1H-pyrrolo[2,3-c]pyridine (compound 1d) (700.0 mg, 95%) as a white solid. LCMS (ESI): [M+H] + =278.9.

[0643] Step 4: Synthesis of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 1e)

[0644]

[0645] At 0 °C, NaH (167.8 mg, 60%) was added to a solution of 5-chloro-2-iodo-1H-pyrrolo[2,3-c]pyridine (compound 1d) (970.0 mg, 3.48 mmol) in THF (5.0 mL). The mixture was stirred at 0 °C under N2 for 2 hours. Then, a solution of CH3I (70.8 mg, 0.44 mmol) in THF (5.0 mL) was added dropwise to the mixture. The mixture was stirred at 0 °C under N2 for 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 1e) (800.0 mg, 79%) as a white solid. LCMS(ESI):[M+H] + =292.9.

[0646] Step 5: Synthesis of 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]phenol (compound 1 g)

[0647]

[0648] To a stirred solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (200.0 mg, 0.68 mmol) in dioxane (compound 1e) (10.0 mL) and H₂O (1.0 mL), 2-hydroxyphenylboronic acid (compound 1f) (113.7 mg, 0.82 mmol), Pd(dppf)Cl₂ (100.6 mg, 0.13 mmol), and K₂CO₃ (283.5 mg, 2.05 mmol) were added to the mixture. The resulting mixture was stirred under N₂ at 80 °C for 16 hours. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]phenol (compound 1 g) (130.0 mg, 73%) as a white solid. LCMS (ESI): [M+H] + =259.1.

[0649] Step 6: Synthesis of N-[2-(2-hydroxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (Compound 1)

[0650]

[0651] To a stirred solution of 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]phenol (compound 1 g) (120.0 mg, 0.46 mmol) in dioxane (5.0 mL), cyclopropaneformamide (compound 1 h) (118.4 mg, 1.39 mmol), BrettPhos Pd G3 (42.5 mg, 0.05 mmol), BrettPhos (49.9 mg, 0.09 mmol), and Cs₂CO₃ (453.8 mg, 1.39 mmol) were added. The resulting mixture was stirred at 100 °C under N₂ for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (0.1% NH4HCO3), mobile phase B: ACN; flow rate: 50 mL / min; gradient: from 43% B to 64% B over 7 minutes; detector: UV 254 nm. The result was N-[2-(2-hydroxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 1) (26.8 mg, 19%) as a white solid. LCMS (ESI): [M+H] + =308.0. 1H NMR (300MHz, DMSO-d6): δ10.47(s,1H),9.97(s,1H),8.57(s,1H),8.18(s,1H),7.35-7.27( m,2H),7.02-6.91(m,2H),6.39(s,1H),3.64(s,3H),2.07-1.99(m,1H),0.81-0.75(m,4H).

[0652] Example S2: Synthesis of N-(2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 2)

[0653]

[0654] Step 1: Synthesis of 5-chloro-2-(2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 2b)

[0655]

[0656] 2-Methoxyphenylboronic acid (124.9 mg, 0.82 mol) and K₂CO₃ (283.5 mg, 2.05 mmol) were added to a stirred solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 2a) (200.0 mg, 0.68 mmol) in dioxane (10.0 mL) and H₂O (1.0 mL). The resulting mixture was stirred at 80 °C under N₂ for 16 hours. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 5-chloro-2-(2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 2b) (170.0 mg, 91%) as a yellow solid. LCMS (ESI): [M+H] + =273.1.

[0657] Step 2: Synthesis of N-[2-(2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 2)

[0658]

[0659] To a stirred solution of 5-chloro-2-(2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 2b) (170.0 mg, 0.63 mmol) in dioxane (5.0 mL), cyclopropaneformamide (compound 2c) (159.5 mg, 1.87 mmol), BrettPhos Pd G3 (56.5 mg, 0.06 mmol), BrettPhos (66.9 mg, 0.15 mmol), and Cs₂CO₃ (609.8 mg, 1.87 mmol) were added. The resulting mixture was stirred at 100 °C for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (0.05% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 17% B to 40% B over 7 minutes; detector: UV 254 / 220 nm, yielding N-[2-(2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 2) (63.2 mg, 32%) as a white solid. LCMS (ESI): [M+H] + =322.1. 1 H NMR (300MHz, DMSO-d6): δ10.52(s,1H),8.60(s,1H),8.17(s,1H),7.55-7.49(m,1H),7.39-7.35(m,1H),7.21(d ,J=8.4Hz,1H),7.12-7.07(m,1H),6.43(s,1H),3.81(s,3H),3.60(s,3H),2.03-1.98(m,1H),0.81-0.76(m,4H).

[0660] Example S3: Synthesis of N-[2-(2-ethoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 3)

[0661]

[0662] Step 1: Synthesis of 5-chloro-2-(2-ethoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 3c)

[0663]

[0664] Pd(dppf)Cl2 (55.8 mg, 0.06 mmol) and K2CO3 (283.5 mg, 2.05 mmol) were added to a stirred mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 3a) (200.0 mg, 0.68 mmol) and 2-ethoxyphenylboronic acid (compound 3b) (226.9 mg, 1.36 mmol) in 1,4-dioxane / H2O (5.0 / 0.5 mL). The resulting mixture was stirred at 80 °C under N2 for 12 hours. After the reaction was complete, the reactants were diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give 5-chloro-2-(2-ethoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 3c) (170.0 mg, 87%) as a yellow oil. LCMS (ESI, m / z): [M+H] + =287.1.

[0665] Step 2: Synthesis of N-[2-(2-ethoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 3)

[0666]

[0667] At room temperature under N2, BrettPhos Pd G3 (47.4 mg, 0.05 mmol), Cs2CO3 (511.2 mg, 1.56 mmol), and BrettPhos (56.1 mg, 0.10 mmol) were added to a stirred mixture of 5-chloro-2-(2-ethoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 3c) (150.0 mg, 0.52 mmol) and cyclopropaneformamide (222.5 mg, 2.61 mmol) in dioxane (3.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions (column: Xselect CSH OBD column 30x150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 40% B to 62% B over 8 min; 254 nm; RT1: 7.47 min) to give N-[2-(2-ethoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 3) (59.9 mg, 34%) as a white solid. LCMS (ESI, m / z): [M+H] + =336.2. 1 H NMR (300MHz, DMSO-d6): δ10.47(s,1H),8.59(s,1H),8.19(s,1H),7.52-7.47(m,1H),7.39-7.36(m,1H),7.21-7.18(m,1H),7.1 1-7.06(m,1H),6.41(d,J=0.6Hz,1H),4.14-4.11(m,2H),3.63(s,3H),2.06-1.99(m,1H),1.28-1.23(m,3H),0.84-0.82(m,4H).

[0668] Example S4: Synthesis of N-[2-[2-(2-hydroxyethoxy)phenyl]-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 4)

[0669]

[0670] Step 1: Synthesis of [2-(2-bromophenoxy)ethoxy](tert-butyl)dimethylsilane (compound 4c)

[0671]

[0672] PPh3 (11.3 g, 43.35 mmol) was added to a mixture of 2-bromophenol (compound 4a) (5.0 g, 28.90 mmol) and 2-[(tert-butyldimethylsilyl)oxy]ethanol (compound 4b) (7.6 g, 43.32 mmol) in THF (100.0 mL) at room temperature under N2. Then, DIAD (8.7 g, 43.37 mmol) was added dropwise to the mixture at 0 °C under N2. The resulting mixture was stirred at room temperature for 2 hours. After the reaction was complete, the resulting mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (10 / 1, v / v) to give [2-(2-bromophenoxy)ethoxy](tert-butyl)dimethylsilane (compound 4c) (8.0 g, 83%) as a yellow solid.

[0673] Step 2: Synthesis of tert-butyldimethyl[2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaneborane-2-yl)phenoxy]ethoxy]silane (compound 4e)

[0674]

[0675] Pd(dppf)Cl2 (0.2 g, 0.30 mmol) and KOAc (0.9 g, 9.05 mmol) were added to a mixture of [2-(2-bromophenoxy)ethoxy](tert-butyl)dimethylsilane (compound 4c) (1.0 g, 3.01 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxane)pentaborane (compound 4d) (2.3 g, 9.05 mmol) in dioxane (10.0 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (10 / 1, v / v) to give tert-butyldimethyl[2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaneborane-2-yl)phenoxy]ethoxy]silane (compound 4e) (700.0 mg, 61%) as a white solid.

[0676] Step 3: Synthesis of 2-(2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]phenyl)-5-chloro-1-methylpyrrolo[2,3-c]pyridine (compound 4g)

[0677]

[0678] Pd(dppf)Cl2 (75.0 mg, 0.10 mmol) and K2CO3 (425.2 mg, 3.07 mmol) were added to a mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 4f) (300.0 mg, 1.02 mmol) and tert-butyldimethyl[2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)phenoxy]ethoxy]silane (compound 4e) (1.1 g, 3.07 mmol) in dioxane / H2O (10.0 / 1.0 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reactants were diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (5 / 1, v / v) to give 2-(2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]phenyl)-5-chloro-1-methylpyrrolo[2,3-c]pyridine (compound 4 g) (100.0 mg, 23%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =417.2.

[0679] Step 4: Synthesis of N-[2-(2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]phenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 4i)

[0680]

[0681] At room temperature under N2, Brettphos (20.5 mg, 0.03 mmol), Brettphos Pd G3 (17.3 mg, 0.02 mmol), and Cs2CO3 (187.5 mg, 0.57 mmol) were added to a mixture of 2-(2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]phenyl)-5-chloro-1-methylpyrrolo[2,3-c]pyridine (compound 4 g) (80.0 mg, 0.19 mmol) and cyclopropaneformamide (compound 4 h) (65.3 mg, 0.76 mmol) in dioxane (2.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the reactants were diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give N-[2-(2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]phenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 4i) (68.0 mg, 76%) as a white solid. LCMS (ESI, m / z): [M+H] + =466.2.

[0682] Step 5: Synthesis of N-[2-[2-(2-hydroxyethoxy)phenyl]-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 4)

[0683]

[0684] A solution of N-[2-(2-[2-[(tert-butyldimethylsilyl)oxy]ethoxy]phenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 4i) (68.0 mg, 0.14 mmol) in HCl / 1,4-dioxane (2.0 mL, 4 mol / L) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions (column: Xselect CSH OBD column 30x150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 22% B to 48% B over 9 min; 220 nm; RT1: 8.03) to give N-[2-[2-(2-hydroxyethoxy)phenyl]-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 4) (15.1 mg, 29%) as a white solid. LCMS (ESI, m / z): [M+H] + =352.2.1 H NMR (300MHz, DMSO-d6): δ10.47(s,1H),8.59(s,1H),8.19(s,1H),7.52-7.46(m,1H),7.39-7.36(m,1H),7.23-7.20(m,1H),7.11-7 .06(m,1H),6.43(d,J=0.6Hz,1H),4.82-4.79(m,1H),4.09-4.06(m,2H),3.67-3.62(m,5H),2.04-1.97(m,1H),0.84-0.73(m,4H).

[0685] Example S5: Synthesis of N-(2-(2-(2-methoxyethoxy)phenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 5)

[0686]

[0687] Step 1: Synthesis of 1-bromo-2-(2-methoxyethoxy)benzene (compound 5c)

[0688]

[0689] DIAD (3.5 g, 17.35 mmol) was added to a mixture of 2-bromophenol (compound 5a) (2.0 g, 11.56 mmol) and PPh3 (4.5 g, 17.34 mmol), and 2-methoxyethanol (compound 5b) (1.3 g, 17.34 mmol) in THF at 0 °C under N2. The resulting mixture was stirred for 2 hours at room temperature under N2. After the reaction was complete, the resulting mixture was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (4 / 1, v / v) to give 1-bromo-2-(2-methoxyethoxy)benzene (compound 5c) (2.3 g, 86%) as a yellow oil.

[0690] Step 2: Synthesis of 2-[2-(2-methoxyethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (compound 5e)

[0691]

[0692] Pd(dppf)Cl2 (348.2 mg, 0.47 mmol) and KOAc (1.4 g, 14.26 mmol) were added to a mixture of 1-bromo-2-(2-methoxyethoxy)benzene (compound 5c) (1.1 g, 4.76 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxane-pentaborane) (compound 5d) (3.6 g, 14.29 mmol) in dioxane (20.0 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reactants were diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (3 / 1, v / v) to give a yellow oil, 2-[2-(2-methoxyethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (compound 5e) (700.0 mg, 52%). LCMS (ESI, m / z): [M+H] + =279.2.

[0693] Step 3: Synthesis of 5-chloro-2-[2-(2-methoxyethoxy)phenyl]-1-methylpyrrolo[2,3-c]pyridine (compound 5g)

[0694]

[0695] Pd(dppf)Cl2 (55.8 mg, 0.06 mmol) and K2CO3 (283.5 mg, 2.05 mmol) were added to a mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 5f) (200.0 mg, 0.68 mmol) and 2-[2-(2-methoxyethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane-pentaborane (compound 5e) (380.3 mg, 1.36 mmol) in dioxane / H2O (4 / 0.4 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give 5-chloro-2-[2-(2-methoxyethoxy)phenyl]-1-methylpyrrolo[2,3-c]pyridine (compound 5 g) (150.0 mg, 69%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =317.2.

[0696] Step 4: Synthesis of N-(2-(2-(2-methoxyethoxy)phenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 5)

[0697]

[0698] At room temperature, BrettPhos Pd G3 (47.4 mg, 0.05 mmol), Cs2CO3 (511.2 mg, 1.56 mmol), and BrettPhos (56.1 mg, 0.10 mmol) were added to a mixture of 5-chloro-2-[2-(2-methoxyethoxy)phenyl]-1-methylpyrrolo[2,3-c]pyridine (compound 5 g) (150.0 mg, 0.52 mmol) and cyclopropaneformamide (compound 5 h) (222.5 mg, 2.61 mmol) in dioxane (4.0 mL). The resulting mixture was stirred under N2 at 100 °C for 16 hours. After the reaction was complete, the reactants were diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions (column: Xselect CSH OBD column 30x150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 35% B to 57% B over 8 min; 254 nm; RT1: 7.3 min) to give N-(2-(2-(2-methoxyethoxy)phenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 5) (59.9 mg, 34%) as a white solid. LCMS (ESI, m / z): [M+H] + =366.2. 1 H NMR (400MHz, DMSO-d6): δ10.47(s,1H),8.59(s,1H),8.19(s,1H),7.52-7.47(m,1H),7.39-7.37(m,1H),7.21(d,J=8.0Hz,1H),7.12-7. 08(m,1H),6.43(d,J=0.4Hz,1H),4.18-4.16(m,2H),3.64(s,3H),3.60-3.58(m,2H),3.18(s,3H),2.08-2.00(m,1H),0.87-0.84(m,4H).

[0699] Example S6: Synthesis of N-[2-(2-cyanophenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 6)

[0700]

[0701] Step 1: Synthesis of 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]benzonitrile (compound 6b)

[0702]

[0703] 2-Cyanophenylboronic acid (120.7 mg, 0.82 mmol), Pd(dppf)Cl2 (100.6 mg, 0.17 mmol), and K2CO3 (283.5 mg, 2.05 mmol) were added to a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridin-2-yl]benzonitrile (compound 6b) (130.0 mg, 71%) in dioxane / H2O (10.0 / 1.0 mL). The resulting mixture was stirred at 80 °C under N2 for 16 hours. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]benzonitrile (compound 6b) (130.0 mg, 71%) as a yellow solid. LCMS (ESI): [M+H] + =268.1.

[0704] Step 2: Synthesis of N-[2-(2-cyanophenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 6)

[0705]

[0706] To a solution of 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]benzonitrile (compound 6b) (110.0 mg, 0.41 mmol) in dioxane (5.0 mL), cyclopropaneformamide (compound 6c) (105.0 mg, 1.24 mmol), BrettPhos Pd G3 (37.0 mg, 0.04 mmol), BrettPhos (44.0 mg, 0.08 mmol), and Cs₂CO₃ (401.6 mg, 1.23 mmol) were added. The resulting mixture was stirred at 100 °C for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 35% B to 48% B over 7 min. Detector: UV 254 / 220 nm. The result was N-[2-(2-cyanophenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 6) (28.6 mg, 22%) as a white solid. LCMS (ESI): [M+H] + =317.0. 1 H NMR (300MHz, DMSO-d6): δ10.57(s,1H),8.72(s,1H),8.26(s,1H),8.07(d,J=7.8Hz,1H),7.89-7 .86(m,1H),7.78-7.70(m,2H),6.73(s,1H),3.73(s,3H),2.06-1.94(m,1H),0.82-0.76(m,4H).

[0707] Example S7: Synthesis of N-[2-(3-hydroxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 7)

[0708]

[0709] Step 1: Synthesis of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 7c)

[0710]

[0711] At room temperature under N2, 3-methoxy-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 7a) (200.0 mg, 0.68 mmol) in dioxane (10.0 mL) and H2O (1.0 mL) was added to a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 7a) (200.0 mg, 0.13 mmol), Pd(dppf)Cl2 (100.0 mg, 0.13 mmol), and K2CO3 (283.5 mg, 2.05 mmol). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the mixture was concentrated under vacuum. The residue was purified by rapid column chromatography with CH2Cl2 / MeOH (97 / 3, v / v) to give 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 7c) (150.0 mg, 76%) as a yellow solid. LCMS(ESI,m / z):[M+H] + =287.1.

[0712] Step 2: Synthesis of 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methylphenol (compound 7d)

[0713]

[0714] Boron tribromide (1.5 mL, 1.50 mmol) was added to a solution of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 7c) (140.0 mg, 0.49 mmol) in DCM (2.0 mL). The resulting mixture was stirred at room temperature for 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to give 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methylphenol (compound 7d) (120.0 mg, crude) as a yellow solid. LCMS (ESI, m / z): [M+H] + =273.1.

[0715] Step 3: Synthesis of N-[2-(3-hydroxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 7)

[0716]

[0717] At room temperature under N2, cyclopropaneformamide (compound 7e) (60.8 mg, 0.71 mmol), Brettphos Pd G3 (86.4 mg, 0.09 mmol), BrettPhos (102.3 mg, 0.19 mmol), and Cs2CO3 (465.9 mg, 1.43 mmol) were added to a solution of 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methylphenol (compound 7d) (130.0 mg, 0.47 mmol) in dioxane (2.0 mL). The resulting mixture was stirred at 100 °C for 3 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions (column: Xselect CSHOBD column 30x150 mm, 5 μm; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 5% B to 30% B over 8 minutes; 220 nm) to give N-[2-(3-hydroxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 7) (10.4 mg, 6%) as a white solid. LCMS (ESI, m / z): [M+H] + =322.1. 1 H NMR (300MHz, DMSO-d6): δ10.48(s,1H),9.64(s,1H),8.59(s,1H),8.20(s,1H),7.16-7.11(m,1H),6.96-6.93(m ,1H),6.78-6.76(m,1H),6.38(d,J=0.6Hz,1H),3.55(s,3H),2.05-1.97(m,1H),1.94(s,3H),0.84-0.78(m,4H).

[0718] Example S8: Synthesis of N-[2-(4-hydroxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 8)

[0719]

[0720] Step 1: Synthesis of 4-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-3-methylphenol (compound 8c)

[0721]

[0722] Pd(dppf)Cl2 (100.0 mg, 0.13 mmol) and K2CO3 (283.5 mg, 2.05 mmol) were added to a stirred mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 8a) (200.0 mg, 0.68 mmol) and 4-hydroxy-2-methylphenylboronic acid (compound 8b) (124.6 mg, 0.82 mmol) in dioxane / H2O (2.0 / 0.2 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (3 / 1, v / v) to give 4-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-3-methylphenol (compound 8c) (85.0 mg, 45%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =273.2.

[0723] Step 2: Synthesis of N-[2-(4-hydroxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 8)

[0724]

[0725] At room temperature under N2, Cs2CO3 (304.6 mg, 0.93 mmol), Brettphos (33.4 mg, 0.06 mmol), and BrettPhos Pd G3 (28.2 mg, 0.03 mmol) were added to a stirred mixture of 4-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-3-methylphenol (compound 8c) (85.0 mg, 0.31 mmol) and cyclopropaneformamide (compound 8d) (79.5 mg, 0.93 mmol) in dioxane (2.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions: column: YMC-ActusTriart C18, 20x250 mm, 5 μm, 12 nm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 28% B to 48% B over 8 min; 254 / 220 nm; yielded N-[2-(4-hydroxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 8) (38.0 mg, 37%) as a white solid. LCMS (ESI, m / z): [M+H] + =322.1. 1 H NMR (300MHz, DMSO-d6): δ10.47(s,1H),9.67(s,1H),8.56(s,1H),8.17(s,1H),7.12(d,J=8.1Hz,1H ),6.78-6.69(m,2H),6.35(s,1H),3.54(s,3H),2.07(s,3H),2.04-1.97(m,1H),0.80-0.72(m,4H).

[0726] Example S9: Synthesis of N-[2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 9)

[0727]

[0728] Step 1: Synthesis of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 9b)

[0729]

[0730] 3-Methoxy-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 9a) (200.0 mg, 0.68 mmol) was added to a stirred solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 9a) in dioxane / H₂O (10.0 / 1.0 mL), 3-methoxy-2-methylphenylboronic acid (136.9 mg, 0.82 mmol), Pd(dppf)Cl₂ (50.3 mg, 0.68 mmol), and K₂CO₃ (283.5 mg, 2.05 mmol) to be added. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 9b) (150.0 mg, 77%) as a yellow solid. LCMS (ESI): [M+H] + =287.1.

[0731] Step 2: Synthesis of N-[2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 9)

[0732]

[0733] To a stirred solution of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 9b) (150.0 mg, 0.53 mmol) in dioxane (5.0 mL), cyclopropaneformamide (133.5 mg, 1.59 mmol), BrettPhos Pd G3 (47.2 mg, 0.02 mmol), BrettPhos (56.1 mg, 0.15 mmol), and Cs₂CO₃ (511.9 mg, 1.59 mmol) were added. The resulting mixture was stirred at 100 °C for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 16% B to 25% B over 7 min. Detector: UV 254 / 220 nm. The result was N-[2-(3-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 9) (74.2 mg, 42%) as a white solid. LCMS (ESI): [M+H] +=336.2. 1 H NMR (400MHz, DMSO-d6): δ10.51(s,1H),8.61(s,1H),8.21(s,1H),7.34-7.30(m,1H),7.12(d,J=8.0Hz,1 H), 6.93 (d, J = 7.2Hz, 1H), 6.41 (s, 1H), 3.86 (s, 3H), 3.55 (s, 3H), 2.03-1.98 (m, 4H), 0.84-0.79 (m, 4H).

[0734] Example S10: Synthesis of N-[2-(4-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 10)

[0735]

[0736] Step 1: Synthesis of 5-chloro-2-(4-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 10b)

[0737]

[0738] 4-Methoxy-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 10a) (200.0 mg, 0.68 mmol) was added to a stirred solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 10a) in dioxane (10.0 mL) and H₂O (1.0 mL) with stirring. The resulting mixture was stirred at 80 °C under N₂ for 16 hours. After the reaction was complete, the resulting mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 5-chloro-2-(4-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 10b) (190.0 mg, 97%) as a white solid. LCMS (ESI): [M+H] + =287.1.

[0739] Step 2: Synthesis of N-[2-(4-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 10)

[0740]

[0741] To a stirred solution of 5-chloro-2-(4-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 10b) (190.0 mg, 0.63 mmol) in dioxane (10.0 mL), cyclopropaneformamide (compound 10c) (169.7 mg, 1.98 mmol), BrettPhos Pd G3 (60.6 mg, 0.06 mmol), BrettPhos (71.3 mg, 0.13 mmol), and Cs₂CO₃ (647.6 mg, 1.98 mmol) were added. The resulting mixture was stirred at 100 °C under N₂ for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30 x 250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 29% B to 55% B over 10 minutes; detector: UV 254 nm. The result was N-[2-(4-methoxy-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 10) (115.9 mg, 52%) as a white solid. LCMS (ESI): [M+H] + =336.2. 1 H NMR (300MHz, DMSO-d6): δ10.49(s,1H),8.58(s,1H),8.18(s,1H),7.25(d,J=8.4Hz,1H),6.97(d,J=2.1Hz,1H) ,6.91-6.87(m,1H),6.38(s,1H),3.81(s,3H),3.54(s,3H),2.13(s,3H),2.07-1.99(m,1H),0.81-0.75(m,4H).

[0742] Example S11: Synthesis of N-[2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 11)

[0743]

[0744] Step 1: Synthesis of 5-chloro-2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 11c)

[0745]

[0746] Pd(dppf)Cl2 (100.0 mg, 0.13 mmol) and K2CO3 (283.0 mg, 2.05 mmol) were added to a stirred mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 11a) (200.0 mg, 0.68 mmol) and 2-methoxy-6-methylphenylboronic acid (compound 11b) (136.0 mg, 0.82 mmol) in dioxane / H2O (2.0 / 0.2 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (3 / 1, v / v) to give 5-chloro-2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 11c) (60.0 mg, 30%) as a white solid. LCMS (ESI, m / z): [M+H] + =287.1.

[0747] Step 2: Synthesis of N-[2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 11)

[0748]

[0749] Cs₂CO₃ (170.4 mg, 0.52 mmol), Brettphos (18.7 mg, 0.03 mmol), and BrettPhos Pd G₃ (15.8 mg, 0.02 mmol) were added to a stirred mixture of 5-chloro-2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 11c) (50.0 mg, 0.17 mmol) and cyclopropaneformamide (compound 11d) (44.5 mg, 0.52 mmol) in dioxane (2.0 mL). The resulting mixture was stirred at 100 °C under N₂ for 16 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 46% B to 60% B over 8 min; 254 nm; yielded N-[2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 11) (14.5 mg, 25%) as a white solid. LCMS (ESI, m / z): [M+H] + =336.1. 1 H NMR (300MHz, DMSO-d6): δ10.47(s,1H),8.58(s,1H),8.17(s,1H),7.42-7.36(m,1H),7.01- 6.97(m,2H),6.34(s,1H),3.70(s,3H),3.47(s,3H),2.06-1.96(m,4H),0.81-0.75(m,4H).

[0750] Example S12: Synthesis of N-[2-(5-fluoro-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 12)

[0751]

[0752] Step 1: Synthesis of 5-chloro-2-(5-fluoro-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 12c)

[0753]

[0754] To a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 12a) (300.0 mg, 1.06 mmol) in dioxane / H₂O (10.0 / 1.0 mL), 5-fluoro-2-methylphenylboronic acid (compound 12b) (189.8 mg, 1.23 mmol), Pd(dppf)Cl₂ (75.5 mg, 0.13 mmol), and K₂CO₃ (425.5 mg, 3.77 mmol) were added. The reaction mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2, v / v) to give 5-chloro-2-(5-fluoro-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 12c) (200.0 mg, 71%) as a yellow oil. LCMS(ESI,m / z):[M+H] + =275.1.

[0755] Step 2: Synthesis of N-[2-(5-fluoro-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 12)

[0756]

[0757] Under N2 atmosphere, a solution of 5-chloro-2-(5-fluoro-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 12c) (180.0 mg, 0.65 mmol) in dioxane (10.0 mL) was supplemented with cyclopropaneformamide (compound 12d) (167.3 mg, 1.96 mmol), BrettPhos (35.7 mg, 0.06 mmol), BrettPhos Pd G3 (118.9 mg, 0.13 mmol), and Cs2CO3 (640.4 mg, 1.96 mmol). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with CH2Cl2 / CH3OH (10 / 1, v / v), followed by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 49% B to 79% B over 7 min; 254 nm) to give N-[2-(5-fluoro-2-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 12) (42.1 mg, 20%) as a white solid. LCMS (ESI, m / z): [M+H] + =324.2. 1 H NMR (400MHz, DMSO-d6): δ10.50(s,1H),8.63(s,1H),8.23(s,1H),7.46-7.42(m,1H),7.31- 7.22(m,2H),6.48(s,1H),3.59(s,3H),2.14(s,3H),2.08-1.99(m,1H),0.84-0.77(m,4H).

[0758] Example S13: Synthesis of N-[1-methyl-2-(4-methyl-2,3-dihydro-1H-indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 13)

[0759]

[0760] Step 1: Synthesis of 5-bromo-4-methyl-2,3-dihydro-1H-indole (compound 13b)

[0761]

[0762] NaBH3CN (1.0 g, 16.72 mmol) was added to a solution of 5-bromo-4-methyl-1H-indole (compound 13a) (880.0 mg, 4.18 mmol) in HOAc (15.0 mL) at 0 °C under N2. The resulting mixture was stirred at room temperature for 2 hours. After the reaction was complete, the pH of the mixture was adjusted to 9 with NaOH (aqueous solution). The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase rapid chromatography with petroleum ether / EtOAc (3 / 1, v / v) to give 5-bromo-4-methyl-2,3-dihydro-1H-indole (compound 13b) (800.0 mg, 90%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =212.0.

[0763] Step 2: Synthesis of tert-butyl 5-bromo-4-methyl-2,3-dihydroindole-1-carboxylic acid (compound 13c)

[0764]

[0765] At room temperature, DMAP (460.8 mg, 3.72 mmol) was added to a mixture of 5-bromo-4-methyl-2,3-dihydro-1H-indole (800.0 mg, 3.77 mmol) and Boc₂O (2.5 g, 11.32 mmol) in DCM (20.0 mL). The resulting mixture was stirred at room temperature for 16 hours. After the reaction was complete, the reaction mixture was diluted with H₂O and extracted with CH₂Cl₂. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / EtOAc (8 / 1, v / v) to give tert-butyl 5-bromo-4-methyl-2,3-dihydroindole-1-carboxylic acid (780.0 mg, 66%) as a white solid. LCMS (ESI, m / z): [M+H] + =312.1.

[0766] Step 3: Synthesis of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (compound 13e)

[0767]

[0768] KOAc (697.8 mg, 7.12 mmol) and Pd(dppf)Cl2 (173.4 mg, 0.23 mmol) were added to a mixture of tert-butyl 5-bromo-4-methyl-2,3-dihydroindole-1-carboxylic acid (compound 13c) (740.0 mg, 2.3 mmol) and bis(pinacol)diborone (compound 13d) (1.8 g, 7.12 mmol) in dioxane (20.0 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give tert-butyl 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-2,3-dihydroindole-1-carboxylic acid (compound 13e) (750.0 mg, 88%) as a white solid. LCMS (ESI, m / z): [M+H] + =360.2.

[0769] Step 4: Synthesis of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (compound 13g)

[0770]

[0771] Pd(PPh3)4 (118.5 mg, 0.10 mmol) and K2CO3 (425.2 mg, 3.07 mmol) were added to a mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (300.0 mg, 1.02 mmol) and 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (442.1 mg, 1.21 mmol) in dioxane / H2O (5.0 / 0.5 mL) at room temperature under N2. The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (170.0 mg, 41%) as a white solid. LCMS (ESI, m / z): [M+H] + =398.2.

[0772] Step 5: Synthesis of 5-[5-cyclopropionylamino-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (compound 13i)

[0773]

[0774] At room temperature under N2, tert-butyl 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-2,3-dihydroindole-1-carboxylic acid (compound 13 g) (150.0 mg, 0.37 mmol) and cyclopropaneformamide (compound 13 h) (128.3 mg, 1.50 mmol) in dioxane (3.0 mL) were added to a mixture of these compounds. Brettphos Pd G3 (34.1 mg, 0.03 mmol), BrettPhos (40.0 mg, 0.07 mmol), and Cs2CO3 (368.4 mg, 1.13 mmol) were stirred at 100 °C for 16 hours. After the reaction was complete, the mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (3 / 7, v / v) to give 5-[5-cyclopropionylamino-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (compound 13i) (150.0 mg, 89%) as a white solid. LCMS (ESI, m / z): [M+H] + =447.2.

[0775] Step 6: Synthesis of N-[1-methyl-2-(4-methyl-2,3-dihydro-1H-indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 13)

[0776]

[0777] TFA (1.0 mL) was added to a solution of 5-[5-cyclopropionylamino-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-2,3-dihydroindole-1-carboxylic acid tert-butyl ester (compound 13i) (160.0 mg, 0.35 mmol) in DCM (2.0 mL) at room temperature. The resulting mixture was stirred at room temperature for 3 hours. After the reaction was complete, the resulting mixture was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions (column: XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 32% B to 62% B over 10 min; 254 nm) to give N-[1-methyl-2-(4-methyl-2,3-dihydro-1H-indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 13) (29.2 mg, 23%) as a white solid. LCMS (ESI, m / z): [M+H] + =347.2. 1 H NMR (300MHz, DMSO-d6): δ10.45(s,1H),8.54(s,1H),8.16(s,1H),6.88(d,J=7.8Hz,1H),6.43(d,J=7.8Hz, 1H),6.29(s,1H),5.76(s,1H),3.55-3.49(m,5H),2.96-2.91(m,2H),2.01-1.99(m,4H),0.82-0.75(m,4H).

[0778] Example S14: Synthesis of N-(1-methyl-2-(6-methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 14)

[0779]

[0780] Step 1: Synthesis of 5-bromo-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (compound 14b)

[0781]

[0782] NaH (342.7 mg, 60%) was added to a solution of 5-bromo-6-methyl-1H-indole (compound 14a) (1.0 g, 4.76 mmol) in THF (20.0 mL) at 0 °C under N2. The resulting mixture was stirred at 0 °C under N2 for 1 hour. Then, SEM-Cl (1.2 g, 7.14 mmol) was added to the mixture at 0 °C. The resulting mixture was stirred at 0 °C under N2 for 1 hour. After the reaction was complete, the reactants were quenched with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (12 / 1, v / v) to give 5-bromo-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (compound 14b) (1.2 g, 74%) as a yellow oil. LCMS(ESI,m / z):[M+H] + =340.1.

[0783] Step 2: Synthesis of 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (compound 14d)

[0784]

[0785] At room temperature under N2, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxane), compound 14c, 1.1 g, 4.41 mmol, KOAc (432.6 mg, 4.41 mmol), and Pd(dppf)Cl2 (107.5 mg, 0.15 mmol) were added to a solution of 5-bromo-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (compound 14b) (500.0 mg, 1.47 mmol) in dioxane (20.0 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (12 / 1, v / v) to give 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (compound 14d) (260.0 mg, 45%) as a brown oil. LCMS (ESI, m / z): [M+H] + =388.2.

[0786] Step 3: Synthesis of 5-chloro-1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridine (compound 14f)

[0787]

[0788] At room temperature under N2, 5-chloro-2-iodo-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 14e) (196.3 mg, 0.67 mmol), K2CO3 (463.8 mg, 3.36 mmol), and Pd(dppf)Cl2 (49.1 mg, 0.07 mmol) were added to a solution of 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (compound 14d) (260.0 mg, 0.67 mmol), dioxane / H2O (8.0 / 2.0 mL), and N2. The resulting mixture was stirred at 80 °C for 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (3 / 1, v / v) to give 5-chloro-1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridine (compound 14f) (150.0 mg, 52%) as a colorless oil. LCMS (ESI, m / z): [M+H] + =426.2.

[0789] Step 4: Synthesis of N-(1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 14h)

[0790]

[0791] At room temperature under N2, cyclopropaneformamide (compound 14g) (179.8mg, 2.11mmol), Cs2CO3 (344.2mg, 1.06mmol), Brettphos (37.8mg, 0.07mmol), and BrettPhos Pd G3 (31.9mg, 0.04mmol) were added to a solution of 5-chloro-1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridine (compound 14f) (150.0mg, 0.35mmol) in dioxane (10.0mL), and the following agents were added: cyclopropaneformamide (compound 14g) (179.8mg, 2.11mmol), Cs2CO3 (344.2mg, 1.06mmol), Brettphos (37.8mg, 0.07mmol), and BrettPhos Pd G3 (31.9mg, 0.04mmol). The resulting mixture was stirred at 100°C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give N-(1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 14h) (110.0 mg, 65%) as a white solid. LCMS (ESI, m / z): [M+H] + =475.2.

[0792] Step 5: Synthesis of N-(1-methyl-2-(6-methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 14)

[0793]

[0794] At room temperature, TBAF (1.0 mL, 0.95 mmol) and EDA (94.8 mg, 1.58 mmol) were added to a solution of N-(1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 14h) (150.0 mg, 0.32 mmol) in DMF (5.0 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase rapid column chromatography with 5-100% CH3CN in H2O solution, and then purified by preparative HPLC under the following conditions (column: Xselect CSH OBD column, 30 × 150 mm, 5 μm; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 10% B to 35% B over 8 min; 254 nm) to give N-(1-methyl-2-(6-methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 14) (5.6 mg, 5%) as a white solid. LCMS (ESI, m / z): [M+H] + =345.2. 1 H NMR (300MHz, DMSO-d6): δ11.16(s,1H),10.48(s,1H),8.58(s,1H),8.20(s,1H),7.50(s,1H),7.38-7. 36(m,2H),6.44(s,1H),6.39(s,1H),3.54(s,3H),2.19(s,3H),2.05-1.95(m,1H),0.83-0.76(m,4H).

[0795] Example S15: Synthesis of N-[1-methyl-2-(4-methyl-1H-indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 15)

[0796]

[0797] Step 1: Synthesis of 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (compound 15b)

[0798]

[0799] At room temperature, NaH (182.8 mg, 60%) was added to a solution of 5-bromo-4-methyl-1H-indole (800.0 mg, 3.81 mmol) in THF (10.0 mL). The resulting mixture was stirred at 0 °C for 1 hour. Then, [2-(chloromethoxy)ethyl]trimethylsilane (695.1 mg, 4.17 mmol) was added dropwise to the mixture at 0 °C. The resulting mixture was stirred at 0 °C for another 1 hour. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (80 / 20, v / v) to give 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (1.2 g, 92%) as a colorless oil. LCMS(ESI,m / z):[M+H] + =340.1.

[0800] Step 2: Synthesis of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (compound 15d)

[0801]

[0802] To a solution of 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (600.0 mg, 1.76 mmol) in 1,4-dioxane (10.0 mL), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxane), 258.0 mg, 0.35 mmol, and KOAc (519.1 mg, 5.29 mmol) were added. The resulting mixture was stirred at 80 °C under N2 for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to obtain 500.0 mg (crude) of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]indole, a brown solid. LCMS (ESI, m / z): [M+H] + =388.2.

[0803] Step 3: Synthesis of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (compound 15f)

[0804]

[0805] To a solution of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (compound 15d) (500.0 mg, 1.29 mmol) in 1,4-dioxane (10.0 mL), 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 15e) (377.5 mg, 1.29 mmol), Pd(dppf)Cl2 (188.9 mg, 0.26 mmol), Na2CO3 (410.4 mg, 3.88 mmol), and H2O (0.5 mL) were added. The resulting mixture was stirred at 80 °C under N2 for 16 hours. After the reaction was complete, the resulting mixture was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (50 / 50, v / v) to give 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (150.0 mg, 23%) as a brown oil. LCMS (ESI, m / z): [M+H] + =426.2.

[0806] Step 4: Synthesis of N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 15h)

[0807]

[0808] To a solution of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indole (compound 15f) (120.0 mg, 0.28 mmol) in 1,4-dioxane (5.0 mL), cyclopropaneformamide (compound 15g) (119.8 mg, 1.41 mmol), Brettphos Pd G3 (51.1 mg, 0.06 mmol), BrettPhos (60.5 mg, 0.12 mmol), and Cs₂CO₃ (275.3 mg, 0.85 mmol) were added. The resulting mixture was stirred at 100 °C under N₂ for 16 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography using CH2Cl2 / CH3OH (94 / 6, v / v) to give N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 15h) (130.0 mg, 97%) as a brown solid. LCMS (ESI, m / z): [M+H] + =475.2.

[0809] Step 5: Synthesis of N-[1-methyl-2-(4-methyl-1H-indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 15)

[0810]

[0811] Ethylenediamine (63.3 mg, 1.05 mmol) and TBAF (330.5 mg, 1.26 mmol) were added to a solution of N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 15h) (100.0 mg, 0.21 mmol) in DMF (5.0 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30 x 250 mm, 5 μm; mobile phase A: water (10 mmol / L FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 20% B to 60% B over 8 min; 254 nm) to give N-[1-methyl-2-(4-methyl-1H-indol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 15) (7.1 mg, 9%) as a white solid. LCMS (ESI, m / z): [M+H] + =345.3. 1 H NMR (300MHz, DMSO-d6): δ11.27(s,1H),10.45(s,1H),8.57(s,1H),8.27-8.15(m,1H),7.43-7.41(m,1H),7.35(d,J=8.1Hz,1H ),7.04(d,J=8.4Hz,1H),6.56(d,J=8.1Hz,1H),6.38(s,1H),3.55(s,3H),2.33(s,3H),2.04-1.99(m,1H),0.89-0.78(m,4H).

[0812] Example S16: Synthesis of N-(1-methyl-2-(6-methyl-1H-indazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 16)

[0813]

[0814] Step 1: Synthesis of 5-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-6-methyl-1H-indazole (compound 16c)

[0815]

[0816] At room temperature under N2, (6-methyl-1H-iodo-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 16a) (500.0 mg, 1.71 mmol), K2CO3 (708.8 mg, 5.13 mmol), and Pd(PPh3)4 (197.5 mg, 0.17 mmol) were added to a solution of 5-chloro-2-iodo-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 16a) in dioxane / H2O (8.0 / 2.0 mL). The resulting mixture was stirred at 80 °C under N2 for 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give 5-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-6-methyl-1H-indazole (compound 16c) (260.0 mg, 51%) as a white solid. LCMS (ESI, m / z): [M+H] + =297.1.

[0817] Step 2: Synthesis of 5-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (compound 16d)

[0818]

[0819] NaH (68.1 mg, 60%) was added to a solution of 5-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-6-methyl-1H-indazole (compound 16c) (260.0 mg, 0.88 mmol) in 5.0 mL of THF at 0 °C under N2. The resulting mixture was stirred at 0 °C for 1 hour. Then, SEM-Cl (219.1 mg, 1.31 mmol) was added to the mixture at 0 °C under N2. The resulting mixture was stirred at 0 °C under N2 for 1 hour. After the reaction was complete, the reactants were quenched with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give 5-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (compound 16d) (210.0 mg, 56%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =427.2.

[0820] Step 3: Synthesis of N-(1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 16f)

[0821]

[0822] At room temperature under N2, cyclopropaneformamide (compound 16e) (251.1 mg, 2.95 mmol), Cs2CO3 (480.7 mg, 1.48 mmol), Brettphos (52.8 mg, 0.10 mmol), and BrettPhos Pd G3 (44.6 mg, 0.05 mmol) were added to a solution of 5-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (compound 16d) (210.0 mg, 0.49 mmol), in dioxane (10.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give N-(1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 16f) (200.0 mg, 85%) as a white solid. LCMS (ESI, m / z): [M+H] + =476.2.

[0823] Step 4: Synthesis of N-(1-methyl-2-(6-methyl-1H-indazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 16)

[0824]

[0825] TBAF (412.3 mg, 1.58 mmol) and EDA (157.7 mg, 2.63 mmol) were added to a solution of N-(1-methyl-2-(6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 16f) (250.0 mg, 0.53 mmol) in DMF (5.0 mL) at room temperature. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase rapid column chromatography with 5-100% CH3CN in H2O solution, followed by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30×250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 24% B to 54% B over 10 min; 254 nm) to give N-(1-methyl-2-(6-methyl-1H-indazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropanecarboxamide (compound 16) (40.4 mg, 22%) as a white solid. LCMS (ESI, m / z): [M+H] + =346.2. 1 H NMR (300MHz, DMSO-d6): δ13.13(s,1H),10.50(s,1H),8.60(s,1H),8.21(s,1H),8.09(s,1H),7.74 (s,1H),7.54(s,1H),6.45(s,1H),3.54(s,3H),2.22(s,3H),2.08-1.98(m,1H),0.84-0.76(m,4H).

[0826] Example S17: Synthesis of N-[1-methyl-2-(6-methyl-1H-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 17)

[0827]

[0828] Step 1: Synthesis of 5-bromo-6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17b)

[0829]

[0830] NaH (181.9 mg, 60%) was added to a solution of 5-bromo-6-methyl-1H-1,3-benzodiazole (compound 17a) (800.0 mg, 3.79 mmol) in 10.0 mL of THF at 0 °C under N2. The resulting mixture was stirred at 0 °C for 1 hour. Then, [2-(chloromethoxy)ethyl]trimethylsilane (695.1 mg, 4.17 mmol) was added dropwise to the mixture at 0 °C. The resulting mixture was stirred at 0 °C for another 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (80 / 20, v / v) to give 5-bromo-6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17b) (900.0 mg, 69%) as a colorless oil. LCMS (ESI, m / z): [M+H] + =341.1.

[0831] Step 2: Synthesis of 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17d)

[0832]

[0833] Pd(dppf)Cl2 (257.2 mg, 0.35 mmol), KOAc (517.6 mg, 5.27 mmol), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxane) (compound 17c) (446.4 mg, 1.76 mmol) were added to a solution of 5-bromo-6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17b) (600.0 mg, 1.76 mmol) in 1,4-dioxane (10.0 mL). The resulting mixture was stirred at 80 °C under N2 for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to give 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17d) (800.0 mg, crude product), a black solid. LCMS (ESI, m / z): [M+H] + =389.2.

[0834] Step 3: Synthesis of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17f)

[0835]

[0836] To a solution of 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17d) (800.0 mg, 2.06 mmol) in 1,4-dioxane (10.0 mL), 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 17e) (602.5 mg, 2.06 mmol), Pd(dppf)Cl2 (301.4 mg, 0.41 mmol), K2CO3 (854.0 mg, 6.18 mmol), and H2O (0.5 mL) were added. The resulting mixture was stirred under N2 at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (65 / 35, v / v) to give a brown oily substance, 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17f) (140.0 mg, 15%). LCMS (ESI, m / z): [M+H] + =427.2.

[0837] Step 4: Synthesis of N-[1-methyl-2-(6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 17h)

[0838]

[0839] To a solution of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 17f) (110.0 mg, 0.26 mmol) in 1,4-dioxane (5.0 mL), cyclopropaneformamide (compound 17g) (109.6 mg, 1.29 mmol), Brettphos Pd G3 (46.7 mg, 0.05 mmol), BrettPhos (55.3 mg, 0.10 mmol), and Cs₂CO₃ (251.8 mg, 0.77 mmol) were added. The resulting mixture was stirred at 100 °C under N₂ for 16 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography using CH2Cl2 / CH3OH (94 / 6, v / v) to give N-[1-methyl-2-(6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 17h) (130.0 mg, 95%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =476.2.

[0840] Step 5: Synthesis of N-(1-methyl-2-(6-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropaneformamide (compound 17)

[0841]

[0842] Ethylenediamine (63.2 mg, 1.05 mmol) and TBAF (329.8 mg, 1.26 mmol) were added to a solution of N-[1-methyl-2-(6-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 17h) (100.0 mg, 0.21 mmol) in DMF (5.0 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 20% B to 60% B over 8 min; 254 nm) to give N-[1-methyl-2-(6-methyl-1H-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 17) (7.9 mg, 10%) as a white solid. LCMS (ESI, m / z): [M+H] + =346.3. 1 H NMR (300MHz, DMSO-d6): δ10.46(s,1H),8.59(s,1H),8.25-8.20(m,2H),7.58-7.54( m,2H),6.43(s,1H),3.54(s,3H),2.20(s,3H),2.03-1.97(m,1H),0.89-0.72(m,4H).

[0843] Example S18: Synthesis of N-[1-methyl-2-(4-methyl-1H-indazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 18)

[0844]

[0845] Step 1: Synthesis of 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18b)

[0846]

[0847] NaH (170.5 mg, 60%) was added to a solution of 5-bromo-4-methyl-1H-indazole (compound 18a) (500.0 mg, 2.39 mmol) in THF (10.0 mL) at 0 °C under N2. The mixture was stirred at 0 °C for 1 hour. Then, a solution of SEM-Cl (592.4 mg, 3.53 mmol) in THF (10.0 mL) was added dropwise to the mixture at 0 °C. The mixture was stirred at 0 °C for another 2 hours. After the reaction was complete, the reactants were quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (5 / 1 v / v) to give 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18b) (800.0 mg, 90%) as a yellow oil. LCMS(ESI):[M+H] + =341.1.

[0848] Step 2: Synthesis of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18d)

[0849]

[0850] To a solution of 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18b) (760.0 mg, 2.27 mmol) in dioxane (10.0 mL), bis(pinacol)diboron (compound 18c) (1.7 g, 6.80 mmol), Pd(dppf)Cl2 (162.9 mg, 0.23 mmol), and KOAc (655.8 mg, 6.80 mmol) were added. The resulting mixture was stirred at 80 °C under N2 for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2, v / v) to give 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18d) (700.0 mg, 81%) as a white solid. LCMS (ESI): [M+H] + =389.2.

[0851] Step 3: Synthesis of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18f)

[0852]

[0853] To a solution of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18d) (400.0 mg, 1.03 mmol) in dioxane / H₂O (20.0 / 2.0 mL), 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 18e) (301.4 mg, 1.03 mmol), Pd(PPh₃)₄ (119.1 mg, 0.13 mmol) and K₃PO₄ (655.3 mg, 3.09 mmol) were added. The resulting mixture was stirred at 100 °C under N₂ for 12 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18f) (300.0 mg, 68%) as a white solid. LCMS (ESI): [M+H] + =427.2.

[0854] Step 4: Synthesis of N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 18h)

[0855]

[0856] To a solution of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole (compound 18f) (300.0 mg, 0.73 mmol) in dioxane (10.0 mL), cyclopropaneformamide (compound 18g) (179.7 mg, 2.18 mmol), BrettPhos (75.4 mg, 0.14 mmol), BrettPhosPd G3 (63.6 mg, 0.07 mmol), and Cs₂CO₃ (686.7 mg, 2.18 mmol) were added. The resulting mixture was stirred at 100 °C under N₂ for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 18h) (140.0 mg, 42%) as a red solid. LCMS (ESI): [M+H] + =476.2.

[0857] Step 5: Synthesis of N-[1-methyl-2-(4-methyl-1H-indazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 18)

[0858]

[0859] Ethylenediamine (88.4 mg, 1.47 mmol) and TBAF (230.8 mg, 0.88 mmol) were added to a solution of N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]indazole-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 18h) (140.0 mg, 0.29 mmol) in DMF (7.0 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v), followed by preparative HPLC under the following conditions: column: YMC-ActusTriart C18, 30x150 mm, 5 μm; mobile phase A: water (0.1% NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 23% B to 53% B over 10 min; detector: UV 254 nm, yielding N-[1-methyl-2-(4-methyl-1H-indazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 18) (16.5 mg, 16%) as a white solid. LCMS (ESI): [M+H] + =346.1. 1 H NMR (300MHz, DMSO-d6): δ13.22(s,1H),10.48(s,1H),8.61(s,1H),8.26-8.21(m,2H),7.49(d,J=8.4Hz, 1H), 7.30 (d, J = 8.7Hz, 1H), 6.45 (s, 1H), 3.57 (s, 3H), 2.43 (s, 3H), 2.08-1.97 (m, 1H), 0.82-0.76 (m, 4H).

[0860] Example S19: Synthesis of N-[1-methyl-2-(4-methyl-1H-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 19)

[0861]

[0862] Step 1: Synthesis of 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19b)

[0863]

[0864] NaH (0.3 g, 60%) was added to a solution of 5-bromo-4-methyl-1H-1,3-benzodiazole (compound 19a) (1.00 g, 4.73 mmol) in THF (10.0 mL) at 0 °C under N2. The resulting mixture was stirred at 0 °C for 1 hour. Then, SEM-Cl (1.2 g, 7.07 mmol) was added dropwise to the mixture at 0 °C under N2. The resulting mixture was stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The resulting mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19b) (1.0 g, 61%) as a yellow oil. LCMS(ESI,m / z):[M+H] + =341.1.

[0865] Step 2: Synthesis of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19d)

[0866]

[0867] Pd(dppf)Cl2 (227.2 mg, 0.27 mmol) and KOAc (819.4 mg, 8.35 mmol) were added to a mixture of 5-bromo-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19b) (950.0 mg, 2.78 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxane) (compound 19c) (2.1 g, 8.34 mmol) in dioxane (10.0 mL) at room temperature under N2. The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give a yellow oily substance, 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19d) (2.0 g, crude). LCMS (ESI, m / z): [M+H] + =389.2.

[0868] Step 3: Synthesis of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19f)

[0869]

[0870] Pd(dppf)Cl2 (70.0 mg, 0.08 mmol) and K2CO3 (354.0 mg, 2.51 mmol) were added to a mixture of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19d) (1.0 g, 2.51 mmol) and 5-chloro-2-iodo-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 19e) (250.0 mg, 0.86 mmol) in dioxane / H2O (10.0 / 1.0 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19f) (350.0 mg, 31%) as a white solid. LCMS (ESI, m / z): [M+H] + =427.2.

[0871] Step 4: Synthesis of N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 19h)

[0872]

[0873] At room temperature under N2, BrettPhosPd G3 (63.6 mg, 0.07 mmol), Cs2CO3 (686.7 mg, 2.10 mmol), and BrettPhos (75.4 mg, 0.14 mmol) were added to a mixture of 5-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazole (compound 19f) (300.0 mg, 0.70 mmol) and cyclopropaneformamide (compound 19g) (239.1 mg, 2.81 mmol) in dioxane (5.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with dichloromethane / methyl alcohol (10 / 1, v / v) to give N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 19h) (220.0 mg, 65%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =476.2.

[0874] Step 5: Synthesis of N-[1-methyl-2-(4-methyl-1H-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 19)

[0875]

[0876] TBAF (280.3 mg, 1.07 mmol) was added to a mixture of N-[1-methyl-2-(4-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 19h) (170.0 mg, 0.36 mmol) and EDA (107.2 mg, 1.79 mmol) in DMF (2.0 mL) at room temperature. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reactants were diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30x150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 19% B to 41% B over 7 min; 254 nm) to give N-[1-methyl-2-(4-methyl-1H-1,3-benzodiazol-5-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 19) (31.4 mg, 25%) as a white solid. LCMS (ESI, m / z): [M+H] + =346.1. 1 HNMR (300MHz, DMSO-d6): δ12.74-12.60(m,1H),10.49(s,1H),8.61(s,1H),8.32(s,1H),8.21(s,1H),7.51(b r,s,1H),7.17(d,J=8.1Hz,1H),6.44(s,1H),3.58(s,3H),2.40(s,3H),2.04-2.00(m,1H),0.83-0.75(m,4H).

[0877] Example S20: Synthesis of N-[1-methyl-2-(3-methylpyridin-2-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 20)

[0878]

[0879] Step 1: Synthesis of 3-methyl-2-(tributyltinyl)pyridine (compound 20b)

[0880]

[0881] At -78°C under N2, n-BuLi (4.1 mL, 64.15 mmol) was added dropwise to a solution of 2-bromo-3-methylpyridine (compound 20a) (5.0 g, 29.06 mmol) in THF (125.0 mL). The resulting mixture was stirred at -78°C for 1 hour. Then, tributyltin chloride (11.3 g, 34.8 mmol) was added dropwise to the mixture at -78°C. The resulting mixture was stirred at -78°C for another 1 hour. After the reaction was complete, the reaction mixture was quenched with saturated NH4Cl and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (80 / 20, v / v) to give 3-methyl-2-(tributyltinyl)pyridine (compound 20b) (300.0 mg, 3%) as a colorless oil. LCMS(ESI):[M+H] + =384.2.

[0882] Step 2: Synthesis of 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-3-methylpyridine (compound 20d)

[0883]

[0884] To a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 20c) (200.0 mg, 0.68 mmol) in DMF (2.0 mL), 3-methyl-2-(tributyltinyl)pyridine (compound 20b) (522.6 mg, 1.36 mmol), CuI (13.0 mg, 0.07 mmol), LiCl (86.9 mg, 2.05 mmol), and Pd(PPh3)4 (79.0 mg, 0.07 mmol) were added. The resulting mixture was irradiated with microwave (MW) at 160 °C for 15 min under N2. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (90 / 10, v / v) to give 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-3-methylpyridine (compound 20d) (170.0 mg, 96%) as a yellow oil. LCMS (ESI): [M+H] + =258.1.

[0885] Step 3: Synthesis of N-[1-methyl-2-(3-methylpyridin-2-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 20)

[0886]

[0887] To a solution of 2-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-3-methylpyridine (compound 20d) (210.0 mg, 0.81 mmol) in 1,4-dioxane (10.0 mL), Brettphos Pd G3 (147.7 mg, 0.16 mmol), BrettPhos (174.9 mg, 0.32 mmol), Cs₂CO₃ (796.4 mg, 2.44 mmol), and cyclopropaneformamide (compound 20e) (104.0 mg, 1.22 mmol) were added. The resulting mixture was stirred at 100 °C for 2 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with CH2Cl2 / CH3OH (94 / 6, v / v), followed by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 18% B to 42% B over 8 min; 254 nm) to give N-[1-methyl-2-(3-methylpyridin-2-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 20) (11.7 mg, 4%) as a white solid. LCMS (ESI, m / z): [M+H] + =307.3. 1 H NMR (300MHz, DMSO-d6): δ10.52(s,1H),8.67(s,1H),8.60-8.58(m,1H),8.24(s,1H),7.87-7.84(m,1H),7 .44-7.40(m,1H),6.67(d,J=0.6Hz,1H),3.73(s,3H),2.35(s,3H),2.08-2.00(m,1H),0.85-0.78(m,4H).

[0888] Example S21: Synthesis of N-[1-methyl-2-(2-methylpyridin-3-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 21)

[0889]

[0890] Step 1: Synthesis of 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methylpyridine (compound 21b)

[0891]

[0892] To a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 21a) (200.0 mg, 0.68 mmol) in dioxane / H₂O (10.0 / 1.0 mL), 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxanepentoboran-2-yl)pyridine (179.8 mg, 0.08 mmol), Pd(dppf)Cl₂ (10.0 mg, 0.01 mmol), and K₂CO₃ (283.5 mg, 2.05 mmol) were added. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 2 v / v) to give 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methylpyridine (compound 21b) (150.0 mg, 85%) as a yellow solid. LCMS (ESI): [M+H] + =258.1.

[0893] Step 2: Synthesis of N-[1-methyl-2-(2-methylpyridin-3-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 21)

[0894]

[0895] To a solution of 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methylpyridine (compound 21b) (150.0 mg, 0.77 mmol) in dioxane (5.0 mL), cyclopropaneformamide (188.3 mg, 2.22 mmol), BrettPhos Pd G3 (66.8 mg, 0.07 mmol), BrettPhos (79.4 mg, 0.17 mmol), and Cs₂CO₃ (720.6 mg, 2.22 mmol) were added. The resulting mixture was stirred at 100 °C for 4 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions: column: YMC-Actus Triart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 27% B to 38% B over 8 minutes; detector: UV 254 / 220 nm, yielding N-[1-methyl-2-(2-methylpyridin-3-yl)pyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 21) (81.7 mg, 46%) as a white solid. LCMS (ESI): [M+H] + =307.2. 1 H NMR (300MHz, DMSO-d6): δ10.52(s,1H),8.64-8.59(m,2H),8.22(s,1H),7.80-7.76(m,1H),7. 41-7.37(m,1H),6.53(s,1H),3.59(s,3H),2.37(s,3H),2.05-1.95(m,1H),0.82-0.76(m,4H).

[0896] Example S22: Synthesis of N-[2-(2-methoxypyridin-3-yl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 22)

[0897]

[0898] Step 1: Synthesis of 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methoxypyridine (compound 22c)

[0899]

[0900] Pd(dppf)Cl2 (83.7 mg, 0.10 mmol) and K2CO3 (425.2 mg, 3.07 mmol) were added to a mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 22a) (300.0 mg, 1.02 mmol) and 2-methoxypyridin-3-ylboronic acid (compound 22b) (313.7 mg, 2.05 mmol) in dioxane / H2O (4.0 / 0.4 mL) at room temperature under N2. The resulting mixture was stirred at 80 °C for 12 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (2 / 1, v / v) to give 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methoxypyridine (compound 22c) (230.0 mg, 82%) as a white solid. LCMS (ESI, m / z): [M+H] + =274.1.

[0901] Step 2: Synthesis of N-[2-(2-methoxypyridin-3-yl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropaneformamide (compound 22)

[0902]

[0903] At room temperature under N2, Cs2CO3 (357.1 mg, 1.10 mmol), BrettPhos (39.2 mg, 0.07 mmol), and BrettPhos Pd G3 (33.1 mg, 0.03 mmol) were added to a stirred mixture of 3-[5-chloro-1-methylpyrrolo[2,3-c]pyridin-2-yl]-2-methoxypyridine (compound 22c) (100.0 mg, 1.82 mmol) in dioxane (3.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions (column: YMC-ActusTriart C18, 30x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 37% B to 67% B over 7 min; 254 nm) to give N-[2-(2-methoxypyridin-3-yl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropanecarboxamide (compound 22) (79.5 mg, 67%) as a white solid. LCMS (ESI, m / z): [M+H] + =323.2. 1 H NMR (300MHz, DMSO-d6): δ10.49(s,1H),8.63(s,1H),8.36-8.34(m,1H),8.21(s,1H),7.86-7.83(m,1H),7 .20-7.16(m,1H),6.52(d,J=0.8Hz,1H),3.92(s,3H),3.64(s,3H),2.03-1.98(m,1H),0.84-0.78(m,4H).

[0904] Example S23: Synthesis of cis-2-(hydroxymethyl)-N-(2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropane-1-carboxamide (compound 23)

[0905]

[0906] Step 1: Synthesis of 6-chloro-4-iodopyridine-3-amine hydrochloride (compound 23b)

[0907]

[0908] A solution of (6-chloro-4-iodopyridin-3-yl)carbamate tert-butyl ester (compound 23a) (5.0 g, 14.10 mmol) in HCl / 1,4-dioxane (50.0 mL, 4 mol / L) was stirred at room temperature for 2 hours. After the reaction was complete, the resulting mixture was concentrated under reduced pressure to give 6-chloro-4-iodopyridin-3-amine hydrochloride (compound 23b) (5.0 g, crude product) as a yellow solid. LCMS (ESI, m / z): [M+H] + =254.9.

[0909] Step 2: Synthesis of 5-chloro-2-(2-methoxyphenyl)-1H-pyrrolo[2,3-c]pyridine (compound 23d)

[0910]

[0911] At room temperature under N2, 1-ethynyl-2-methoxybenzene (compound 23c) (1.3 g, 9.43 mmol), Na2CO3 (4.2 g, 39.3 mmol), LiCl (333.2 mg, 7.86 mmol), and Pd(dppf)Cl2 (575.1 mg, 0.79 mmol) were added to a solution of 6-chloro-4-iodopyridin-3-amine hydrochloride (compound 23b) (2.0 g, crude) in DMF (20.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (50 / 50, v / v) to give 5-chloro-2-(2-methoxyphenyl)-1H-pyrrolo[2,3-c]pyridine (compound 23d) (770.0 mg, 37%) as a brown solid. LCMS (ESI, m / z): [M+H] + =259.1.

[0912] Step 3: Synthesis of 5-chloro-2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 23e)

[0913]

[0914] NaH (371.1 mg, 60%) was added to a solution of 5-chloro-2-(2-methoxyphenyl)-1H-pyrrolo[2,3-c]pyridine (compound 23d) (770 mg, 2.98 mmol) in THF (10.0 mL) at 0 °C under N2. The resulting mixture was stirred at 0 °C under N2 for 1 hour. Then, CH3I (2.2 g, 15.5 mmol) was added dropwise to the mixture at 0 °C under N2. The resulting mixture was stirred at 0 °C for another 1 hour. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 5-chloro-2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 23e) (800.0 mg, crude) as a brown solid. LCMS(ESI,m / z):[M+H] + =273.2.

[0915] Step 4: Synthesis of 2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine-5-amine (compound 23g)

[0916]

[0917] Diphenylmethyleneimine (compound 23f) (1.6 g, 8.80 mmol), t-BuOK (987.5 mg, 8.80 mmol), XantPhos (339.5 mg, 0.59 mmol), and Pd2(dba)3 (268.6 mg, 0.29 mmol) were added to a solution of 5-chloro-2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 23e) (800.0 mg, crude) in toluene (10.0 mL) at room temperature under N2. The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography using CH2Cl2 / CH3OH (87 / 13, v / v) to give 2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine-5-amine (compound 23 g) (240.0 mg, 15%) as a brown solid. LCMS (ESI, m / z): [M+H] + =254.1.

[0918] Step 5: Synthesis of (cis)-2-((2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)carbamoyl)cyclopropane-1-carboxylic acid methyl ester (compound 23i)

[0919]

[0920] At 0 °C and under N2, cis-2-(methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine-5-amine (compound 23 g) (240.0 mg, 0.95 mmol) in a solution of 2-(2-methoxycarbonyl)cyclopropane-1-carboxylic acid (compound 23 h) (136.6 mg, 0.95 mmol), DIEA (612.3 mg, 4.74 mmol), and HATU (432.3 mg, 1.14 mmol) were added to the solution of 2-(2-methoxycarbonyl)cyclopropane-1-carboxylic acid (compound 23 h) in DMF (5.0 mL). The resulting mixture was stirred at room temperature for 2 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 99, v / v) to give methyl (cis)-2-((2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)carbamoyl)cyclopropane-1-carboxylic acid (compound 23i) (190.0 mg, 53%) as a brown solid. LCMS (ESI, m / z): [M+H] + =380.2.

[0921] Step 6: Synthesis of cis-2-(hydroxymethyl)-N-(2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropane-1-carboxamide (compound 23)

[0922]

[0923] NaBH4 (169.5 mg, 4.48 mmol) was added to a solution of (cis)-2-((2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)carbamoyl)cyclopropane-1-carboxylic acid methyl ester (compound 23i) (170.0 mg, 0.45 mmol) in THF / CH3OH (5.0 / 1.0 mL) at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After the reaction was complete, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions (column: XBridgePrep OBD C18 column, 19x250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: MeOH- preparative; flow rate: 25 mL / min; gradient: from 54% B to 70% B over 7 min; 254 nm) to give cis-2-(hydroxymethyl)-N-(2-(2-methoxyphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropane-1-carboxamide (compound 23) (5.3 mg, 3%) as a white solid. LCMS (ESI, m / z): [M+H] + =352.2. 1 H NMR (300MHz, DMSO-d6): δ10.40(s,1H),8.59(s,1H),8.21(s,1H),7.56-7.50(m,1H),7.39-7.36(m,1H),7.21(d,J=8.1Hz,1H),7.13-7.08( m,1H),6.42(d,J=0.6Hz,1H),4.48-4.45(m,1H),3.82(s,3H),3.69-3.55(m,5H),2.10-2.07(m,1H),1.50-1.34(m,1H),0.98-0.90(m,2H).

[0924] Example S24: Synthesis of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 24)

[0925]

[0926] Step 1: Synthesis of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 24c)

[0927]

[0928] Under N2 conditions, K2CO3 (708.7 mg, 5.12 mmol), 3-methoxy-2-methylphenylboronic acid (compound 24b) (425.5 mg, 2.56 mmol), and Pd(dppf)Cl2 (250.1 mg, 0.34 mmol) were added to a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 24a) (500.0 mg, 1.70 mmol) in 1,4-dioxane / H2O (36.0 / 3.6 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with ether / ethyl acetate (87 / 13, v / v) to give 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 24c) (380.0 mg, 77%) as a yellow solid. LCMS (ESI, m / z): [M+H] + =287.1.

[0929] Step 2: Synthesis of 3-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-2-methylphenol (compound 24d)

[0930]

[0931] BBr3 (1616.2 mg, 6.45 mmol) was added to a solution of 5-chloro-2-(3-methoxy-2-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridine (compound 24c) (380.0 mg, 1.32 mmol) in CH2Cl2 (5.0 mL) at 0 °C under N2. The resulting mixture was stirred at 0 °C for 2.5 h. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with ether / ethyl acetate (85 / 15, v / v) to give 3-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-2-methylphenol (compound 24d) (380.0 mg, 99%) as a yellow solid. LCMS(ESI,m / z):[M+H] + =273.1.

[0932] Step 3: Synthesis of (1S,2S)-2-fluoro-N-(2-(3-hydroxy-2-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropane-1-carboxamide (compound 24)

[0933]

[0934] At room temperature under N2, Cs2CO3 (716.8 mg, 2.20 mmol), (1S,2S)-2-fluorocyclopropane-1-carboxamide (compound 24e) (378.0 mg, 3.66 mmol), BrettPhos (157.4 mg, 0.29 mmol), and Brettphos Pd G3 (132.9 mg, 0.14 mmol) were added to a solution of 3-(5-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-2-methylphenol (compound 24d) (200.0 mg, 0.73 mmol), in dioxane (10.0 mL). The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (80 / 20, v / v), followed by preparative HPLC under the following conditions (column: Xselect CSH OBD column 30 × 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 20% B to 38% B over 8 min; 220 nm) to give (1S,2S)-2-fluoro-N-(2-(3-hydroxy-2-methylphenyl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)cyclopropane-1-carboxamide (compound 24) (10.7 mg, 4%) as a white solid. LCMS (ESI, m / z): [M+H] + =340.1. 1 HNMR (300MHz, DMSO-d6): δ10.46(s,1H),9.57(s,1H),8.53(s,1H),8.14(s,1H),7.11-7.03(m,1H),6.87(d,J=8.1Hz,1H),6.71(d, J=7.5Hz,1H),6.33(s,1H),4.95-4.71(m,1H),3.48(s,3H),2.17-2.08(m,1H),1.87(s,3H),1.61-1.54(m,1H),1.11-1.02(m,1H).

[0935] Example S25: Synthesis of (1S,2S)-2-fluoro-N-[2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 25)

[0936]

[0937] Step 1: Synthesis of 5-chloro-2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 25c)

[0938]

[0939] At room temperature under N2, 2-methoxy-6-methylphenylboronic acid (compound 25b) (204.3 mg, 1.23 mmol), K2CO3 (425.3 mg, 3.08 mmol), and Pd(dppf)Cl2 (75.1 mg, 0.10 mmol) were added to a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 25a) (300.0 mg, 1.03 mmol) in 1,4-dioxane / H2O (8.0 mL / 2.0 mL). The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (1 / 1, v / v) to give 5-chloro-2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 25c) (90.0 mg, 30%) as a brown oil. LCMS (ESI, m / z): [M+H] + =287.1.

[0940] Step 2: Synthesis of (1S,2S)-2-fluoro-N-[2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 25)

[0941]

[0942] At room temperature under N2, (1S,2S)-2-fluorocyclopropane-1-carboxamide (compound 25d) (107.9 mg, 1.05 mmol), BrettPhos (22.5 mg, 0.04 mmol), Cs2CO3 (204.5 mg, 0.63 mmol), and BrettPhos Pd G3 (19.0 mg, 0.02 mmol) were added to a solution of 5-chloro-2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 25c) (60.0 mg, 0.21 mmol) in 1,4-dioxane (6.0 mL). The reaction mixture was stirred in a microwave at 120 °C for 1.5 h under N2. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by preparative HPLC under the following conditions (column: XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 40% B to 70% B over 7 min; 254 nm) to give (1S,2S)-2-fluoro-N-[2-(2-methoxy-6-methylphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 25) (10.3 mg, 13%) as a white solid. LCMS (ESI, m / z): [M+H] + =354.2. 1 HNMR (400MHz, DMSO-d6): δ10.50(s,1H),8.59(s,1H),8.19(s,1H),7.41-7.37(m,1H),7.02-6.98(m,2H),6.36(s,1H) ,4.99-4.81(m,1H),3.70(s,3H),3.48(s,3H),2.25-2.19(m,1H),2.06(s,3H),1.68-1.61(m,1H),1.15-1.10(m,1H).

[0943] Example S26: Synthesis of (1S,2S)-2-fluoro-N-[2-(5-fluoro-2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 26)

[0944]

[0945] Step 1: Synthesis of 5-chloro-2-(5-fluoro-2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 26c)

[0946]

[0947] A mixture of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 26a) (500.0 mg, 1.71 mmol), 5-fluoro-2-methoxyphenylboronic acid (compound 26b) (348.6 mg, 2.05 mmol), K₂CO₃ (708.8 mg, 5.13 mmol), and Pd(dppf)Cl₂ (125.1 mg, 0.17 mmol) in dioxane (10.0 mL) and H₂O (2.0 mL) was stirred under N₂ for 16 hours at 100 °C. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography using CH2Cl2 / CH3OH (94 / 6, v / v) to give 5-chloro-2-(5-fluoro-2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 26c) (483.5 mg, 97%) as a white solid. LCMS (ESI, m / z): [M+H] + =291.1.

[0948] Step 2: Synthesis of (1S,2S)-2-fluoro-N-[2-(5-fluoro-2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 26)

[0949]

[0950] A mixture of 5-chloro-2-(5-fluoro-2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 26c) (150.0 mg, 0.52 mmol), (1S,2S)-2-fluorocyclopropane-1-carboxamide (compound 26d) (63.8 mg, 0.62 mmol), Cs₂CO₃ (213.9 mg, 1.55 mmol), BrettPhos (55.4 mg, 0.10 mmol), and BrettPhos Pd G₃ (46.8 mg, 0.05 mmol) in dioxane (5.0 mL) was irradiated with microwave at 100 °C for 2 hours. After the reaction was complete, the resulting mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by rapid column chromatography with CH2Cl2 / CH3OH (94 / 6, v / v), followed by preparative HPLC under the following conditions (column: YMC-Actus Triart C18, 30 × 250 mm, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: from 25% B to 55% B over 10 min; 254 nm) to give (1S,2S)-2-fluoro-N-[2-(5-fluoro-2-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 26) (10.4 mg, 5%) as a white solid. LCMS (ESI, m / z): [M+H] + =358.1. 1 H NMR (300MHz, DMSO-d6): δ10.52(s,1H),8.62(s,1H),8.21(s,1H),7.44-7.33(m,1H),7.29-7.20(m,2H),6.49( s,1H),5.04-4.76(m,1H),3.79(s,3H),3.62(s,3H),2.28-2.15(m,1H),1.71-1.58(m,1H),1.15-1.03(m,1H).

[0951] Example S27: Synthesis of (1S,2S)-2-fluoro-N-[2-(2-fluoro-6-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 27)

[0952]

[0953] Step 1: Synthesis of 5-chloro-2-(2-fluoro-6-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 27c)

[0954]

[0955] At room temperature under N2, 2-fluoro-6-methoxyphenylboronic acid (compound 27b) (209.2 mg, 1.23 mmol), K2CO3 (425.3 mg, 3.08 mmol), and Pd(dppf)Cl2 (75.05 mg, 0.10 mmol) were added to a solution of 5-chloro-2-iodo-1-methylpyrrolo[2,3-c]pyridine (compound 27a) (300.0 mg, 1.03 mmol) in 1,4-dioxane / H2O (5.0 / 1.0 mL). The resulting mixture was stirred at 80 °C for 3 hours. After the reaction was complete, the resulting mixture was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by rapid column chromatography with petroleum ether / ethyl acetate (52 / 48, v / v) to give 5-chloro-2-(2-fluoro-6-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 27c) (100.0 mg, 33%) as a white solid. LCMS (ESI, m / z): [M+H] + =291.0.

[0956] Step 2: Synthesis of (1S,2S)-2-fluoro-N-[2-(2-fluoro-6-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridin-5-yl]cyclopropane-1-carboxamide (compound 27)

[0957]

[0958] At room temperature under N2, (1S,2S)-2-fluorocyclopropane-1-carboxamide (compound 27d) (265.9 mg, 2.58 mmol), Cs2CO3 (504.3 mg, 1.55 mmol), BrettPhos (55.4 mg, 0.10 mmol), and Brettphos Pd G3 (46.77 mg, 0.05 mmol) were added to a solution of 5-chloro-2-(2-fluoro-6-methoxyphenyl)-1-methylpyrrolo[2,3-c]pyridine (compound 27c) (150.0 mg, 0.52 mmol) in 1,4-dioxane (5.0 mL). The resulting mixture was stirred at 100 °...

Claims

1. A compound of formula (IA): or a pharmaceutically acceptable salt thereof, wherein: X is NR 3’ or CR 3 , Y is NR 2 or CR 4 , When X is NR 3’ When Y is CR 4 , Y has to CR 5 double bond, and X has to CR 5 or when X is CR 3 When Y is NR 2 , Y has to CR 5 single bond, and X has a 5 Double bonds; m is an integer from 0 to 3; Each R 1 are independently -D, -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 、C1-C3 alkylene-NR 7’ R 8’ , C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 、C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 、C1-C2 alkylene-(4 to 8 membered heterocycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ 、C1-C2 alkylene-(C3-C7 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 or C1-C2 alkylene-(C3-C7 heterocycloalkylene)-(C o -C2 alkylene)-NR 7’ R 8’ , where R 1 wherein the alkyl, alkylene, cycloalkylene and heterocycloalkylene moieties are optionally substituted with 1-3 fluorine atoms and / or 1-6 deuterium atoms, and wherein each heterocyclic nitrogen atom, if present, is independently optionally substituted with C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl; R 2 is -H, C1-C3 alkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted by 1-3 fluorine atoms and / or 1-6 deuterium atoms; R 3 is -H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen or -CN; R 3’ is -H, C1-C3 alkyl, -C3-C6 cycloalkyl or -CN; R 4 is -H, C1-C3 alkyl or halogen, wherein the C1-C3 alkyl is optionally substituted by 1-3 fluorine atoms and / or 1-6 deuterium atoms; R 5 is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is optionally substituted by 1-5 R 9 Group substitution; Each R 7 are independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN or C1-C6 heteroalkyl; Each R 8 are independently -H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN or C1-C6 heteroalkyl; Each pair of R 7’ and R 8’ Together with the nitrogen atom to which they are attached, independently form a 3- to 8-membered heterocyclic ring, wherein the heterocyclic ring optionally contains an additional 1-2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocyclic nitrogen atom, if present, is independently optionally substituted with C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl; Each R 9 are independently halogen, -OR 10 、-NR 7 R 8 , C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, -CN, S(O) n C1-C3 alkyl or S(O) n C3-C6 cycloalkyl, wherein n is an integer from 0 to 2; and Each R 10 It is independently -H, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl, C1-C3 alkoxy and / or 1 to 6 deuterium atoms.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (IA) is a compound of formula (IAi) or formula (IA-ii): in m is an integer of 0 or 2; Each R 1 are independently -F, C1-C3 alkyl, C1-C3 alkylene-NR 7 R 8 、C1-C3 alkylene-NR 7’ R 8’ , C1-C3 alkylene-OH, C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7 R 8 , C1-C3 alkylene-CN, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7 R8 or C1-C2 alkylene-(C4-C6 heterocycloalkylene)-(C0-C2 alkylene)-NR 7’ R 8’ , where R 1 wherein the alkyl, alkylene, cycloalkylene and heterocycloalkylene are optionally substituted by 1-3 fluorine atoms and / or 1-6 deuterium atoms, and wherein each heterocyclic nitrogen atom, if present, is independently optionally substituted by C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl; R 2 is -H, -CH3, CD3, -CHF2 or -CH2CH3; R 3 is -H, C1-C3 alkyl, C3-cycloalkyl, halogen or -CN; R 3’ is -H, C1-C3 alkyl, C3-cycloalkyl or -CN; R 4 is -H, -CH3, -CD3, -CHF2, -CH2CH3 or halogen; R 5 is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: in indicates a single bond or a double bond, and wherein the 5- to 10-membered heteroaryl is optionally substituted by 1-5 R 9 Group substitution; Each R 7 are independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN or C2-C3 heteroalkyl; Each R 8 are independently -H, C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkyl-CN or C2-C3 heteroalkyl; Each pair of R 7’ and R 8’ Together with the nitrogen atom to which they are attached, independently form a 4- to 6-membered heterocyclic ring, wherein the heterocyclic ring optionally contains an additional 1-2 heteroatoms selected from the group consisting of N, O and S, and wherein each heterocyclic nitrogen atom, if present, is independently optionally substituted with C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN or C2-C3 heteroalkyl; Each R 9 are independently halogen, -OR 10, C1-C3 alkyl, -CF2H, -CF3, C3-C6 cycloalkyl or -CN, and Each R 10 It is independently -H, C1-C3 alkyl, -CD3, -CF2H, -CF3 or C3-C6 cycloalkyl, wherein the C1-C3 alkyl is optionally substituted with hydroxyl and / or C1-C3 alkoxy and / or 1-6 deuterium atoms.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Each R 1 are independently -F, C1-C3 alkylene-NR 7 R 8’ or C1-C3 alkylene-OH; and Where R 1 Each pair of R 7’ and R 8’ Together with the nitrogen atom to which they are attached, they independently form a 4- to 6-membered heterocyclic ring, wherein the heterocyclic ring optionally contains an additional 1-2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atom of any primary or secondary amine present in the heterocyclic ring is optionally substituted with -H or C1-C3 alkyl.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 5 is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: in indicates a single bond or a double bond, and wherein the 5- to 10-membered heteroaryl is optionally substituted by 1-3 R 9 Group substitution.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 2 is -CH3, -CD3 or -CH2CH3; R 3 is -H, -F, -CH3 or -CN; R 3’ is -H or -CH3; and R 4 It is -H, -F or -CH3.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Each R 9 are independently -F, -Cl, -OR 10 , -CH3 or -CN, and Each R 10is independently -H, -CH3, -CD3 or -CH2CH3, wherein said -CH3 or said -CH2CH3 is optionally replaced by hydroxyl and / or -OCH 3 replace.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (IA) is a compound of formula (IAi) or formula (IA-ii): in m is an integer 0 or 1; R 1 -F, C1-C3 alkylene-NR 7 R 8’ or C1-C3 alkylene-OH; R 2 is -CH3, -CD3 or -CH2CH3; R 3 is -H, -F, -CH3 or -CN; R 3’ is -H or -CH3; R 4 is -H, -F or -CH3; R 5 is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: in indicates a single bond or a double bond, and wherein the 5- to 10-membered heteroaryl is optionally substituted by 1-3 R 9 Group substitution; Each pair of R 7’ and R 8’ Together with the nitrogen atom to which they are attached, independently form a 4- to 6-membered heterocyclic ring, wherein the heterocyclic ring optionally contains an additional 1-2 heteroatoms selected from the group consisting of N and O, and wherein the nitrogen atom of any primary or secondary amine present in the heterocyclic ring is optionally substituted with -H or C1-C3 alkyl; Each R 9 are independently -F, -Cl, -OR 10 , -CH3 or -CN, and Each R 10 Independently -H, -CH3, -CD3 or -CH2CH3, wherein said -CH3 or said -CH2CH3 is optionally substituted with hydroxyl and / or -OCH3.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (IA) is a compound of formula (IAi) or formula (IA-ii): in m is an integer 0 or 1; R 1 for -F; R 2 is -CH3; R 3 is -H or -CH3; R 3’ is -H or -CH3; R 4 is -CH3; R 5 is a 5- to 10-membered heteroaryl group, wherein the 5- to 10-membered heteroaryl group is selected from the group consisting of: wherein the 5- to 10-membered heteroaryl is optionally substituted by 1-3 R 9 Group substitution; Each R 9 Independently -F or -OR 10 ,and Each R 10 is independently -H, -CH3 or -CD3.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Each R 9 Independently -F, -OR 10 or -CH3, and Each R 10 are independently -H, -CH3, -CD3, -CF2H or -CF3.

10. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

11. A method of treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or mixed phenotype acute leukemia in a human in need thereof, comprising administering to the human a compound of claim 1, or a pharmaceutically acceptable salt thereof.

12. The method of claim 11, wherein the leukemia is a refractory leukemia.

13. The method of claim 12, wherein the human suffering from refractory leukemia has one or more mutations in the Bcr-Abl tyrosine kinase gene that result in specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

14. The method of claim 13, wherein the human suffering from refractory leukemia has a mutation in the Bcr-Abl tyrosine kinase gene that results in a specific amino acid substitution, T315I.

15. The method of claim 11, further comprising administering one or more pharmaceutical agents.

16. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising the compound according to claim 16, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

18. A compound having the following structure: or a pharmaceutically acceptable salt thereof.

19. A method of treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or mixed phenotype acute leukemia in a human in need thereof, comprising administering to the human a compound of claim 18, or a pharmaceutically acceptable salt thereof.

20. The method of claim 19, wherein the leukemia is a refractory leukemia.

21. The method of claim 20, wherein the human suffering from refractory leukemia has one or more mutations in the Bcr-Abl tyrosine kinase gene that result in specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

22. The method of claim 21, wherein the human suffering from refractory leukemia has a mutation in the Bcr-Abl tyrosine kinase gene that results in a specific amino acid substitution, T315I.

23. The method of claim 19, further comprising administering one or more pharmaceutical agents.

24. A pharmaceutical composition comprising the compound of claim 18, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

25. A method of treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia in a human in need thereof, comprising administering to the human a compound of claim 16, or a pharmaceutically acceptable salt thereof.

26. The method of claim 25, wherein the leukemia is a refractory leukemia.

27. The method of claim 26, wherein the human suffering from refractory leukemia has one or more mutations in the Bcr-Abl tyrosine kinase gene that result in specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

28. The method of claim 27, wherein the human suffering from refractory leukemia has a mutation in the Bcr-Abl tyrosine kinase gene that results in a specific amino acid substitution, T315I.

29. The method of claim 25, further comprising administering one or more pharmaceutical agents.

30. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 2 is -H or -CH3; R 3 is -H; R 3’ is -H; and R 4 It is -H or -CH3.

31. A compound having the following structure: or a pharmaceutically acceptable salt thereof.

32. A method of treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or mixed phenotype acute leukemia in a human in need thereof, comprising administering to the human a compound of claim 31, or a pharmaceutically acceptable salt thereof.

33. The method of claim 32, wherein the leukemia is a refractory leukemia.

34. The method of claim 33, wherein the human suffering from refractory leukemia has one or more mutations in the Bcr-Abl tyrosine kinase gene that result in specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

35. The method of claim 34, wherein the human suffering from refractory leukemia has a mutation in the Bcr-Abl tyrosine kinase gene that results in a specific amino acid substitution, T315I.

36. The method of claim 32, further comprising administering one or more pharmaceutical agents.

37. A pharmaceutical composition comprising the compound of claim 31, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

38. A compound having the following structure: or a pharmaceutically acceptable salt thereof.

39. A method of treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or mixed phenotype acute leukemia in a human in need thereof, comprising administering to the human a compound of claim 38, or a pharmaceutically acceptable salt thereof.

40. The method of claim 39, wherein the leukemia is a refractory leukemia.

41. The method of claim 40, wherein the human suffering from refractory leukemia has one or more mutations in the Bcr-Abl tyrosine kinase gene that result in specific amino acid substitutions selected from the group consisting of: M244V, L248V, G250E, G250A, Q252H, Q252R, Y253F, Y253H, E255K, E255V, D276G, F311L, T315N, T315A, F317V, F317L, M343T, M351T, E355G, F359A, F359V, V379I, F382L, L387M, H396P, H396R, S417Y, E459K, F486S, and T315I.

42. The method of claim 41, wherein the human suffering from refractory leukemia has a mutation in the Bcr-Abl tyrosine kinase gene that results in a specific amino acid substitution, T315I.

43. The method of claim 39, further comprising administering one or more pharmaceutical agents.

44. A pharmaceutical composition comprising the compound of claim 38, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them

    US20100210476A1

  • Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC

    US20110312959A1

  • Heterocyclic compounds as protein kinase inhibitors

    US20140155398A1

  • Azaindole derivatives as multi kinase inhibitors

    US20150353539A1

  • Amide derivative and medicine

    WO2005063720A1